https://trial.medpath.com/news/96f7228c2c49accb/organ-sparing-tmli-with-post-transplant-cyclophosphamide-shows-promising-results-for-aml-transplant-patients 2025-03-23T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/b56cfd731226582d/high-dose-vitamin-d-delays-ms-progression-by-over-200-days-in-landmark-clinical-trial 2025-03-23T16:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/dffd4439ed8c8fa6/breakthrough-humanized-antibody-vx-01-shows-promise-against-deadly-mucormycosis 2025-03-23T15:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/cce80212570f5c68/recombinant-zoster-vaccine-shows-strong-efficacy-and-safety-profile-in-rheumatoid-arthritis-patients 2025-03-23T15:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/b051e65e45a99396/rosemary-derived-compound-shows-promise-as-potential-alzheimer-s-treatment-in-preclinical-study 2025-03-23T10:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/94d2aed891eb40e6/golidocitinib-plus-pd-1-antibodies-shows-promise-in-nsclc-patients-after-anti-pd-1-therapy-failure 2025-03-23T07:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/ef45c755351ac51c/abbvie-files-trade-secret-lawsuit-against-genmab-over-adc-technology-in-cancer-drug-development 2025-03-23T02:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/152424c880bff467/immunotherapy-in-gastric-cancer-moving-to-earlier-disease-stages-and-optimizing-combination-approaches 2025-03-23T02:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/b67bf361447084bd/abpi-nihr-and-amrc-join-forces-to-advance-patient-involvement-in-pharmaceutical-research 2025-03-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c94613b76cdf5b69/mit-researchers-develop-antibody-painting-technology-to-enhance-glp-1-drug-delivery 2025-03-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a8a062324051f7f4/wistar-institute-scientists-develop-next-generation-dna-lnp-vaccine-technology-with-enhanced-immune-response 2025-03-22T19:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/a250ac1ce09c7c90/evidence-based-survivorship-care-programs-enhance-quality-of-life-for-cancer-patients 2025-03-22T16:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/07a29fb44825c0be/kalaris-and-allovir-complete-merger-to-advance-novel-anti-vegf-therapy-for-retinal-diseases 2025-03-22T13:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/e4414808628b78db/accelerate-diagnostics-seeks-fda-clearance-for-rapid-antimicrobial-susceptibility-testing-system 2025-03-22T13:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/3e1cbc1b39d6d3c3/elahere-demonstrates-significant-survival-benefit-in-phase-iii-mirasol-trial-for-platinum-resistant-ovarian-cancer 2025-03-22T04:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/8e2dd358c52ec776/formosa-pharmaceuticals-and-cipla-form-strategic-partnership-for-app13007-commercialization-across-11-countries 2025-03-22T01:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/f18b466a0dbeeaf0/igc-pharma-reports-promising-interim-results-for-alzheimer-s-agitation-therapy 2025-03-22T01:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/16e72c1cc937c990/inhaled-insulin-shows-promising-results-in-type-1-diabetes-management-over-30-weeks 2025-03-21T22:35:27+00:00 hourly 0.9 https://trial.medpath.com/news/1948c8b25be9e23a/sugar-based-gel-shows-promise-as-natural-hair-loss-treatment-in-preclinical-study 2025-03-21T22:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/c3195aed9e816d2a/fda-approves-alnylam-s-amvuttra-for-attr-cardiomyopathy-sending-stock-soaring 2025-03-21T22:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/c27b2205977ef043/pfizer-completes-exit-from-haleon-with-3-3-billion-stake-sale 2025-03-21T19:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/8547a567100ff58b/hypera-to-launch-generic-semaglutide-in-brazil-ahead-of-2026-patent-expiration 2025-03-21T19:35:52+00:00 hourly 0.9 https://trial.medpath.com/news/02b43019d394d6be/pln-101095-combined-with-pembrolizumab-shows-promising-activity-in-ici-refractory-solid-tumors 2025-03-21T19:35:40+00:00 hourly 0.9 https://trial.medpath.com/news/b3d9421463ae269d/fda-approves-tremfya-for-crohn-s-disease-and-fabhalta-for-rare-kidney-disease-amid-major-pharma-acquisitions 2025-03-21T19:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/eca78215a8784699/isofol-medical-advances-arfolitixorin-development-with-new-phase-ib-ii-trial-for-metastatic-colorectal-cancer 2025-03-21T19:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/bff397fdcb944504/johnson-johnson-commits-55-billion-to-expand-u-s-manufacturing-and-r-d-capabilities 2025-03-21T18:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/36b967cf9a7bb6a4/china-s-aphranel-magiccrystal-caha-filler-receives-global-regulatory-approvals-setting-new-standards-in-regenerative-aesthetics 2025-03-21T17:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/1946b23f3a3e27b6/new-at-home-urine-test-accurately-detects-aggressive-prostate-cancer-reducing-need-for-invasive-procedures 2025-03-21T17:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/9e01a63f2cead43a/china-s-nmpa-grants-conditional-approval-to-tazemetostat-for-ezh2-mutant-follicular-lymphoma 2025-03-21T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/96f5ebe816191f06/fda-issues-second-rejection-for-rivoceranib-camrelizumab-combination-in-unresectable-liver-cancer 2025-03-21T17:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/eed60efaf2e537b3/phase-iii-illuminate-trial-tilsotolimod-plus-ipilimumab-fails-to-improve-outcomes-in-advanced-refractory-melanoma 2025-03-21T16:37:24+00:00 hourly 0.9 https://trial.medpath.com/news/f61dfac162813dc7/china-grants-conditional-approval-for-tazverik-to-treat-relapsed-or-refractory-follicular-lymphoma 2025-03-21T16:37:15+00:00 hourly 0.9 https://trial.medpath.com/news/6e6ef24a9951c7c8/hlb-group-to-resubmit-riboceranib-for-fda-approval-following-second-rejection 2025-03-21T16:36:32+00:00 hourly 0.9 https://trial.medpath.com/news/ebbb5b41f75f3e86/fda-approves-telix-pharmaceuticals-novel-prostate-cancer-imaging-agent 2025-03-21T16:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/bfb07d4df2a4b2fc/omeros-advances-zaltenibart-phase-3-trials-for-pnh-with-potential-superiority-over-current-treatments 2025-03-21T16:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/c02da53b7d2229f2/yaqrit-secures-ps2-2-million-nihr-grant-for-pivotal-dialive-liver-support-device-trials 2025-03-21T16:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/56ac154f2b1dd25a/mount-sinai-s-personalized-cancer-vaccine-pgv001-shows-promise-across-multiple-tumor-types-in-phase-1-trial 2025-03-21T15:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/53631fb928dc3129/new-report-reveals-critical-insights-into-clinical-stage-pharma-partnerships-from-2020-2025 2025-03-21T13:35:52+00:00 hourly 0.9 https://trial.medpath.com/news/340c1d31aae0e674/astrazeneca-invests-2-5-billion-in-beijing-to-establish-sixth-global-r-d-center 2025-03-21T10:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/40559636354567b3/angle-s-parsortix-system-shows-promise-in-real-time-her2-status-monitoring-for-breast-cancer-patients 2025-03-21T10:33:37+00:00 hourly 0.9 https://trial.medpath.com/news/8b87bdbbaa407b76/pembrolizumab-bevacizumab-combination-shows-promising-survival-outcomes-for-melanoma-brain-metastases 2025-03-21T10:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/407da7d3820b1df5/feinstein-institutes-pioneers-precision-vagus-nerve-stimulation-with-3m-nih-grant 2025-03-21T04:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/e8b49ebb66c4f3f0/study-reveals-factors-influencing-immune-checkpoint-inhibitor-efficacy-in-metastatic-colorectal-cancer 2025-03-21T04:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/6ebcae2b57ce275b/hutchmed-reports-65-growth-in-oncology-products-revenue-achieves-profitability-in-2024 2025-03-21T03:02:23+00:00 hourly 0.9 https://trial.medpath.com/news/3a2138421c8ac983/autolus-therapeutics-advances-obe-cel-into-pivotal-phase-2-trial-for-systemic-lupus-erythematosus 2025-03-21T02:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/0cbbead8ccd11389/fda-grants-ind-clearance-to-triastek-s-3d-printed-once-daily-anticoagulant-t20g 2025-03-21T02:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/eab27a369b7dee74/heidelberg-pharma-reports-promising-clinical-progress-with-hdp-101-in-multiple-myeloma-and-advances-hdp-102-into-clinical-trials 2025-03-21T02:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/8ac21dacffe912db/brain-hemorrhage-treatment-market-expected-to-grow-significantly-by-2032-as-ai-solutions-gain-fda-approval 2025-03-21T01:35:03+00:00 hourly 0.9 https://trial.medpath.com/news/9fd2c206801cd040/fda-approves-alnylam-s-amvuttra-for-attr-cm-expanding-treatment-options-for-cardiomyopathy-patients 2025-03-21T01:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/8f89de422492bf8d/bharat-biotech-invests-75-million-in-india-s-first-integrated-cell-and-gene-therapy-facility 2025-03-21T01:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/e47111afa6b5c007/london-biotechnology-show-2025-returns-with-expanded-platform-for-industry-innovation-and-collaboration 2025-03-21T01:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/40c491995432b0e7/first-infant-successfully-treated-with-novel-gene-therapy-for-rare-metabolic-disorder 2025-03-21T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/015c547e9a61f813/phase-3-moonrise-1-trial-evaluates-tar-210-erdafitinib-system-for-bladder-cancer 2025-03-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5ca4650e38bf17b6/comprehensive-review-identifies-key-biomarkers-for-predicting-gastric-cancer-immunotherapy-response 2025-03-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ef0cdd4d6d6fefa4/canada-expands-access-to-rare-disease-medications-through-provincial-agreements 2025-03-20T23:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/8c8ae97bfc6a012b/fda-advisory-panel-backs-alnylam-s-onpattro-for-attr-cardiomyopathy-despite-efficacy-concerns 2025-03-20T23:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/85fb8ee7d5b0a2c4/curetopia-raises-1-77m-on-solana-blockchain-to-develop-first-treatment-for-aars2-deficiency 2025-03-20T22:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/e6ef60b1bd840992/uva-health-launches-two-national-clinical-trials-to-combat-long-covid 2025-03-20T22:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/6e2d512b25fd2c99/olema-oncology-advances-pivotal-phase-3-trials-for-palazestrant-in-metastatic-breast-cancer 2025-03-20T22:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/5673629a40517906/bd-initiates-pivotal-stance-trial-testing-galaflex-lite-scaffold-for-reducing-capsular-contracture-in-breast-implant-revision-surgery 2025-03-20T22:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/caeb5571939421d3/darzalex-dominates-multiple-myeloma-market-with-11-6-billion-in-global-sales 2025-03-20T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/831781af88911dce/federal-circuit-rules-patent-term-extensions-for-reissue-patents-based-on-original-patent-issue-date 2025-03-20T19:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/71883c48baec2c97/wugen-initiates-pivotal-trial-of-novel-off-the-shelf-car-t-therapy-for-rare-blood-cancers 2025-03-20T19:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/d48cc61267cac5e7/eyenovia-and-betaliq-plan-reverse-merger-to-create-innovative-ophthalmic-technology-company 2025-03-20T19:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/f3797c97eac0333b/windtree-therapeutics-partners-with-evofem-to-manufacture-fda-approved-contraceptive-phexxi 2025-03-20T19:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/768874652f3e18d6/neurizon-initiates-pharmacokinetic-studies-to-resolve-fda-clinical-hold-on-als-drug-nuz-001 2025-03-20T17:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/ecbdfe180ffd322f/clostrabio-secures-invent-illinois-funding-appoints-new-cso-and-prepares-for-microbiome-therapeutic-launch 2025-03-20T17:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/8767350626c69cb1/liscure-biosciences-secures-first-ever-regulatory-approval-for-hair-health-probiotic-ingredient 2025-03-20T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/8338a300e5588a73/bpgbio-to-unveil-novel-e2-based-targeted-protein-degradation-platform-at-european-summit 2025-03-20T16:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/3748bdb1a415f310/kiffik-biomedical-and-rubix-ls-join-forces-to-develop-novel-non-invasive-colorectal-cancer-test 2025-03-20T16:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/f3ae24f402d50156/pathos-ai-initiates-phase-1b-2a-trial-of-pocenbrodib-for-metastatic-castration-resistant-prostate-cancer 2025-03-20T16:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/5f652289eac47d6c/icon-becomes-first-major-cro-to-fully-implement-medidata-s-ai-powered-clinical-data-studio 2025-03-20T16:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/3ae605ab151ab035/esperion-advances-bempedoic-acid-to-phase-3-trials-for-pediatric-familial-hypercholesterolemia 2025-03-20T13:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/05c9fcde007b310a/dsmb-recommends-continuation-of-briacell-s-phase-3-trial-for-metastatic-breast-cancer-immunotherapy 2025-03-20T13:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/42e42d0393a815c4/ionctura-initiates-phase-ii-ocule-01-trial-of-roginolisib-for-metastatic-uveal-melanoma 2025-03-20T13:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/59824310320a9072/sibel-health-secures-30-million-series-c-funding-and-new-fda-clearance-for-interoperable-monitoring-platform 2025-03-20T13:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/5c28afcb42bb3c4f/fda-approves-second-manufacturing-site-for-contrave-bolstering-supply-chain-for-leading-oral-weight-loss-medication 2025-03-20T13:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/1c62a4e4c6031db0/flatiron-health-and-nrg-oncology-partner-to-streamline-clinical-trial-data-management-with-ehr-to-edc-technology 2025-03-20T13:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/8814384e59b65341/intelligent-bio-solutions-secures-sixth-u-s-patent-for-fingerprint-drug-screening-technology 2025-03-20T13:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/403fc9268ce347f3/biomarin-s-voxzogo-shows-promising-results-in-reducing-tibial-bowing-in-children-with-achondroplasia 2025-03-20T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/172d4f8029eadbf8/senti-bio-reports-promising-early-results-for-gene-circuit-car-nk-cell-therapy-in-relapsed-refractory-aml 2025-03-20T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/14b890bbabd8c91d/cepi-awards-4-5-million-to-accelerate-vaccine-development-using-dyadic-s-c1-fungal-platform 2025-03-20T12:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/cca9c44f2f47e8dc/predictive-oncology-sells-skyline-medical-assets-to-deroyal-industries-to-focus-on-ai-driven-cancer-drug-discovery 2025-03-20T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f08e0c8bf6fe7de2/sionna-therapeutics-reports-positive-phase-1-results-for-novel-cystic-fibrosis-nbd1-stabilizers 2025-03-20T11:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/b7cd890cc8ebbc01/pioneering-hiv-remission-trial-in-south-africa-shows-promise-for-drug-free-control 2025-03-20T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/348fdaffcf7e0c9f/sanofi-acquires-dren-bio-s-novel-b-cell-depleter-for-600-million-expanding-immunology-pipeline 2025-03-20T10:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/f86748e9571e7e6f/pharming-group-initiates-phase-ii-trial-of-leniolisib-for-cvid-with-immune-dysregulation 2025-03-20T10:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/9b304a75e031cd84/lupus-research-alliance-awards-4-5-million-to-pioneer-next-generation-cell-therapies-for-lupus 2025-03-20T08:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/c090fc46464a0973/health-canada-approves-hikma-s-kloxxado-r-8-mg-nasal-spray-for-opioid-overdose-treatment 2025-03-20T08:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/7fc6e5ebc8c6512d/merigolix-shows-promise-in-multiple-indications-as-tiumbio-s-oral-gnrh-antagonist-advances-in-clinical-trials 2025-03-20T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/122d65619ec47c96/flatiron-health-breaks-new-ground-with-cross-border-patient-level-oncology-data-sharing 2025-03-20T07:35:26+00:00 hourly 0.9 https://trial.medpath.com/news/ee3a2b010d7da98d/bon-secures-32-million-deal-for-novel-postbiotic-blood-sugar-management-solution 2025-03-20T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6cc24faaac67d167/new-phospholipid-complex-boosts-cbd-bioavailability-for-epilepsy-and-ms-treatment 2025-03-20T04:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/9b4a5afc58743364/fda-grants-de-novo-clearance-to-nanosonics-coris-automated-endoscope-cleaning-system 2025-03-20T04:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/c1528e118adff707/fda-grants-orphan-drug-designation-to-bioinvent-s-bi-1808-for-t-cell-lymphoma-treatment 2025-03-20T03:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/e8272d7e402369a5/paratek-pharmaceuticals-acquires-optinose-for-330-million-to-expand-xhance-access-in-chronic-rhinosinusitis-market 2025-03-20T02:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/3a542d75af1cb14b/savolitinib-plus-tagrisso-r-shows-56-response-rate-in-met-high-lung-cancer-hutchmed-reports 2025-03-20T01:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/fadec70fbf85c3bb/fda-clears-quibim-s-ai-powered-prostate-cancer-detection-tool-for-us-market 2025-03-20T01:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/43d1cd0b4a66da9e/usda-approves-first-autologous-immunotherapy-for-canine-osteosarcoma 2025-03-20T01:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/eb438f0cdb0e3339/ema-proposes-paradigm-shift-to-include-pregnant-and-breastfeeding-women-in-clinical-trials 2025-03-20T01:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/b6ed845887201b92/sitryx-launches-phase-1-trial-of-novel-oral-pkm2-modulator-for-atopic-dermatitis 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1d11fdec9eb98b54/verve-therapeutics-expands-base-editing-trial-for-cholesterol-treatment-into-us-following-fda-clearance 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/be3db7104f78b6b0/neonc-technologies-secures-nasdaq-listing-expands-brain-cancer-clinical-trials-to-india 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/74fbacff8c5c0274/keap1-gene-identified-as-key-driver-of-chemoresistance-in-small-cell-lung-cancer 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/06e7f55e77961b93/rhythm-pharmaceuticals-regains-global-control-of-imcivree-by-reacquiring-rights-in-china 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2c7b2ac884a0187d/everhope-oncology-launches-with-10m-seed-funding-to-transform-cancer-care-in-india 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/128f53acd96afff8/diagnexia-partners-with-artera-to-launch-ai-powered-prostate-cancer-test-in-uk 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/77ea626d3be157f8/navigating-europe-s-complex-market-access-landscape-five-emerging-strategies-for-pharmaceutical-success 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a516628451f5fc92/amphista-therapeutics-advances-novel-brd9-degraders-using-proprietary-targeted-glue-technology 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/41fb76a0ac71a7bb/trump-administration-considers-eliminating-cdc-s-hiv-prevention-division 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3b4b7415a5614e4d/setmelanotide-receives-orphan-drug-designation-in-japan-for-hypothalamic-obesity-treatment 2025-03-19T23:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/944da52fed1e9489/evinova-s-remote-monitoring-technology-integrated-into-major-breast-cancer-platform-trial-to-detect-early-lung-complications 2025-03-19T23:02:40+00:00 hourly 0.9 https://trial.medpath.com/news/010197cbf16ecb3d/virogates-and-sobi-expand-collaboration-on-suparnostic-r-diagnostic-for-kineret-r-treatment 2025-03-19T22:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/507a70fd48d4868c/first-pediatric-dopamine-hydrochloride-formulation-receives-mhra-approval-for-treating-hypotension-in-children 2025-03-19T22:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/d56a4ec11107c805/fda-approves-first-treatment-for-cerebrotendinous-xanthomatosis-ctx-offering-hope-to-patients-with-rare-genetic-disorder 2025-03-19T22:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/465046fae94fbe23/lenz-therapeutics-advances-towards-august-2025-fda-decision-for-novel-presbyopia-eye-drop 2025-03-19T20:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/338785c26501d14e/uric-acid-shows-promise-as-novel-add-on-therapy-for-ischemic-stroke-in-nih-funded-study 2025-03-19T20:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/74c677f2baad1b41/pipeline-progress-over-25-new-therapies-in-development-for-metastatic-liver-cancer 2025-03-19T19:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/c499b6686964fb51/five-year-study-shows-aflibercept-treat-and-extend-regimen-maintains-vision-in-neovascular-amd-patients 2025-03-19T19:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/31d51aa391e9203b/fda-grants-orphan-drug-designation-to-hlx22-for-gastric-cancer-treatment 2025-03-19T19:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/aefba45c218557b4/pomalidomide-based-combinations-show-promising-efficacy-in-relapsed-refractory-multiple-myeloma 2025-03-19T19:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/355a91262b02093e/fda-aligns-with-signal12-on-phase-3-trial-design-for-novel-ocular-gvhd-therapy-pro-ocular 2025-03-19T19:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/eacc647db49a6be3/nhs-england-denies-access-to-life-extending-prostate-cancer-treatments-despite-strong-clinical-evidence 2025-03-19T19:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/d678db0d73fa1665/informeddna-acquires-coriell-life-sciences-to-advance-pharmacogenomics-and-precision-medicine 2025-03-19T17:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/c4935ced39b1618a/google-deepmind-unveils-txgemma-open-ai-models-to-accelerate-drug-discovery 2025-03-19T16:36:37+00:00 hourly 0.9 https://trial.medpath.com/news/7635c7ac26977391/immunovant-halts-regulatory-plans-for-rare-disease-drug-despite-phase-3-success 2025-03-19T16:35:25+00:00 hourly 0.9 https://trial.medpath.com/news/63c91cf0843354bf/eli-lilly-invests-in-ampersand-biomedicines-65m-series-b-for-precision-drug-delivery-platform 2025-03-19T16:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/d0a7392f21330d89/servier-and-black-diamond-therapeutics-forge-780m-global-licensing-deal-for-novel-raf-ras-cancer-therapy 2025-03-19T16:34:27+00:00 hourly 0.9 https://trial.medpath.com/news/200cdcde283002d6/t45-labs-secures-oversubscribed-25m-fund-to-advance-cardiovascular-medical-devices 2025-03-19T16:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/f7e09398c036c0a3/city-of-hope-launches-clinical-trial-testing-osteoporosis-drug-for-type-1-diabetes-treatment 2025-03-19T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/740cf8eacc944876/can-fite-advances-piclidenoson-to-phase-ii-trial-for-rare-lowe-syndrome-with-no-current-treatments 2025-03-19T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/d5484ee532112193/fda-clears-biomerieux-s-vitek-compact-pro-system-to-combat-antimicrobial-resistance 2025-03-19T16:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/9f28b0630a69e8d9/maia-biotechnology-s-novel-cancer-drug-ateganosine-receives-usan-approval-for-nsclc-treatment 2025-03-19T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/dd5fe69fe2ce0fe2/abvc-biopharma-projects-19-million-revenue-from-global-licensing-deals-and-strategic-cdmo-acquisition 2025-03-19T16:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/d6a203dbb9edf4fb/akebia-therapeutics-secures-50-million-through-public-offering-to-advance-kidney-disease-treatments 2025-03-19T16:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/905a545c0e7dba1e/liquidia-secures-100m-financing-to-advance-yutrepia-for-pulmonary-hypertension-treatment 2025-03-19T14:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/7d52e55835080a5d/fda-rejects-hengrui-hlb-liver-cancer-combination-therapy-for-second-time 2025-03-19T14:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/8f1fe381830e9464/merck-to-present-phase-3-zenith-trial-results-for-winrevair-in-high-risk-pah-patients-at-acc-25 2025-03-19T13:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/6adcf78df2844e3b/immunovant-shifts-focus-to-next-gen-therapy-despite-positive-phase-iii-results-for-batoclimab-in-myasthenia-gravis 2025-03-19T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/bd323814c3ba965f/primo-and-abx-partner-to-introduce-advanced-psma-targeting-radiotracer-for-prostate-cancer-diagnosis-in-taiwan 2025-03-19T13:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/972a431b5d5d9d34/vapendavir-shows-promise-in-phase-2-trial-for-rhinovirus-induced-copd-exacerbations 2025-03-19T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/4a4100534f600197/polyrizon-partners-to-develop-novel-intranasal-delivery-system-for-psychedelic-therapeutics 2025-03-19T10:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/875581e9db3ed91f/sobi-launches-phase-2a-trial-of-gamifant-for-interferon-gamma-driven-sepsis 2025-03-19T10:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/836d9698f2a51ec5/germany-adapts-amnog-framework-to-align-with-eu-hta-regulation-for-medicinal-products 2025-03-19T10:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/84cc5dd18cc0a321/ucb-s-investigational-therapy-shows-promising-results-for-rare-mitochondrial-disease-tk2d 2025-03-19T10:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/9a4c97d9e59b17ba/immunovia-s-next-generation-pancreatic-cancer-test-shows-77-detection-rate-in-early-stage-disease 2025-03-19T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/8bce419b68108d19/acrivon-therapeutics-to-showcase-ap3-platform-and-clinical-program-updates-at-upcoming-r-d-event 2025-03-19T08:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/3899204e1a40abc3/hoth-therapeutics-ht-kit-shows-promising-results-against-gastrointestinal-stromal-tumors-in-preclinical-study 2025-03-19T08:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/d02cc73c4419b27a/ipsen-secures-eur500-million-inaugural-rated-public-bond-following-investment-grade-ratings 2025-03-19T07:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/96e03f68dc5b1dc8/lecanemab-s-effectiveness-for-alzheimer-s-may-be-significantly-lower-in-female-patients-study-suggests 2025-03-19T07:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/06c2e84b8e88cbb1/dassault-systemes-invests-in-click-therapeutics-to-advance-digital-therapeutics-beyond-clinical-trials 2025-03-19T07:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/98a89ee3c2e008e7/cellares-revolutionizes-cell-therapy-manufacturing-with-automated-platform-for-autoimmune-and-cancer-treatments 2025-03-19T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/49da8a59baa4aa24/japan-pioneers-decentralized-clinical-trials-in-oncology-to-overcome-geographic-barriers 2025-03-19T02:50:42+00:00 hourly 0.9 https://trial.medpath.com/news/ff0a3a2accc0d603/ir-med-s-pressuresafe-device-shows-90-sensitivity-in-diverse-skin-tone-study-as-company-expands-into-diabetic-foot-ulcer-market 2025-03-19T02:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/98244b41c61056bd/tirzepatide-demonstrates-superior-speed-in-achieving-diabetes-control-and-weight-loss-targets 2025-03-19T02:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/59841dbe291bdfc3/fruquintinib-sintilimab-combination-meets-primary-endpoint-in-phase-ii-iii-rcc-trial 2025-03-19T01:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/4564e90e09060751/moon-surgical-secures-fda-clearance-for-ai-powered-scopilot-on-maestro-system 2025-03-19T01:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/b70939352aba2dc4/fda-approves-groundbreaking-technologies-for-epilepsy-monitoring-embrace-smartwatch-and-minder-implantable-eeg-system 2025-03-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a56729ea5321f2dd/galecto-shifts-focus-to-oncology-with-acquisition-of-dual-enl-yeats-flt3-inhibitor-for-aml-treatment 2025-03-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7fffe87b717742a6/il-17-and-il-23-inhibitors-show-promising-safety-and-efficacy-profiles-in-elderly-psoriasis-patients 2025-03-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e7a1f73b87c281a8/madrigal-s-resmetirom-shows-promise-in-nash-treatment-where-others-have-failed 2025-03-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/32e84c50b9a7e405/aga111-shows-promising-results-in-spinal-fusion-clinical-trial-advances-to-phase-3 2025-03-18T23:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/6492e6081b0ec817/valo-health-and-nference-partner-to-accelerate-ai-driven-drug-discovery 2025-03-18T22:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/7b53606359731f66/nyrada-s-nyr-bi03-shows-promise-in-traumatic-brain-injury-and-begins-phase-1-clinical-trial 2025-03-18T22:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/6dd6c6e6e92e0921/insulet-expands-omnipod-5-automated-insulin-delivery-system-to-australia-and-three-additional-markets 2025-03-18T20:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/0327e2103397da8a/china-approves-record-48-first-in-class-innovative-drugs-in-2023 2025-03-18T19:33:37+00:00 hourly 0.9 https://trial.medpath.com/news/5b9676145724bf29/cs-diagnostics-partners-with-lachman-consultants-to-fast-track-fda-approval-for-novel-cancer-radiation-therapy-hydrogel 2025-03-18T19:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/da6e94b71d4bdf0c/fda-grants-fast-track-designation-for-johnson-johnson-s-nipocalimab-in-sjogren-s-disease 2025-03-18T19:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/f89c8caa7044b069/fda-approved-kidney-drug-sevelamer-shows-promise-in-fighting-antibiotic-resistance 2025-03-18T19:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/a9d576e85b25ff13/phase-iii-trial-shows-hypofractionated-radiation-therapy-safe-and-effective-for-breast-cancer-patients-with-reconstruction 2025-03-18T19:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/b76f054329bafbbd/ascelia-pharma-advances-orviglance-nda-following-positive-fda-meeting-submission-planned-for-mid-2025 2025-03-18T17:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/d3181dfbb647e357/enterobiotix-reports-promising-phase-2a-results-for-novel-microbiome-therapy-in-ibs-c 2025-03-18T16:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/5c1981d863702252/curadel-pharma-advances-first-in-class-zwitterionic-drug-for-ureter-visualization-into-phase-3-trial 2025-03-18T16:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/34b83eb78ad9b552/fda-grants-fast-track-designation-to-nipocalimab-for-sjogren-s-disease-treatment 2025-03-18T16:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/79dfd806dd57c862/fda-clears-trainhealth-s-novel-electrical-stimulation-device-for-neurological-rehabilitation 2025-03-18T16:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/335b01f67f6b1e98/cycle-pharmaceuticals-launches-venxxiva-for-cystinuria-treatment-in-the-us 2025-03-18T16:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/c95318e80603049e/novotech-forms-strategic-partnership-with-knuh-to-advance-regenerative-medicine-trials-in-south-korea 2025-03-18T16:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/ec3828ff4402d0c7/smsbiotech-advances-copd-treatment-with-phase-i-trial-approval-in-australia 2025-03-18T16:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/1f77a5f0de0498a7/umecrine-cognition-s-phase-1b-2a-trial-of-golexanolone-for-pbc-faces-temporary-delay-due-to-manufacturing-issues 2025-03-18T16:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/ec5df5a772522578/fda-accepts-teva-s-applications-for-uzedy-in-bipolar-disorder-and-ajovy-for-pediatric-migraines 2025-03-18T13:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/1dcc6cf5f33a481e/ypsomed-and-camdiab-to-launch-ios-version-of-mylife-loop-automated-insulin-delivery-system 2025-03-18T13:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/8da91b44010b4553/fda-approves-first-liquid-losartan-formulation-for-hypertension-treatment 2025-03-18T13:34:12+00:00 hourly 0.9 https://trial.medpath.com/news/4fb07ae920869f1b/cytrellis-expands-global-reach-ellacor-r-with-micro-coring-r-technology-receives-regulatory-approval-in-canada-and-saudi-arabia 2025-03-18T13:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/09ea00e87e208652/redhill-biopharma-seeks-uk-approval-for-talicia-its-leading-h-pylori-treatment 2025-03-18T13:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/cbc13e87bfda90db/landmark-study-reveals-over-20-of-cancer-patients-eligible-for-pan-cancer-therapies 2025-03-18T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/78198f3b301aabb7/virax-biolabs-launches-clinical-study-to-assess-t-cell-dysfunction-in-post-acute-infection-syndromes 2025-03-18T12:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/ce05be9db5b2595a/madison-scientific-secures-7m-seed-funding-to-advance-smart-hydrocephalus-shunt-technology 2025-03-18T12:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/00400a1c7c6fe051/novartis-s-fabhalta-rapidly-reshapes-pnh-treatment-landscape-as-biosimilars-loom 2025-03-18T12:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/e698671a8a5fdc1e/eton-pharmaceuticals-poised-for-growth-with-expanding-rare-disease-portfolio-and-pending-fda-approvals 2025-03-18T10:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/2ca7faa4bb67dfed/european-pharma-giants-push-for-us-level-drug-pricing-amid-tariff-tensions 2025-03-18T10:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/18c1b6f122cc5944/lilly-s-mounjaro-demonstrates-superior-efficacy-in-head-to-head-trials-against-diabetes-competitors 2025-03-18T10:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/1d365306ffb982c9/hiv-cure-trials-at-croi-2025-show-promise-for-broader-patient-applications 2025-03-18T10:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/e7a8ea2b502cbe50/fda-approves-oncorena-s-ind-for-novel-kidney-specific-cancer-drug-in-dialysis-patients 2025-03-18T10:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/0be6161951ea5cb4/crossject-reports-positive-6-month-stability-data-for-zepizure-epilepsy-auto-injector 2025-03-18T09:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/db03d3684c126eb6/cyrano-therapeutics-advances-novel-treatment-for-post-viral-smell-loss-with-soft-mist-technology 2025-03-18T08:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/8b133d0598692054/prosense-r-cryoablation-shows-promise-as-non-surgical-alternative-for-early-stage-breast-cancer 2025-03-18T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/b09bdda882b7b497/start-acquires-carolina-urologic-research-center-to-strengthen-genitourinary-cancer-trial-capabilities 2025-03-18T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/1c983850b5418a68/omega-laboratories-and-cannabix-technologies-validate-breakthrough-marijuana-breath-detection-method 2025-03-18T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d75eb411e6546e5b/oral-antiviral-obeldesivir-shows-promise-in-treating-ebola-virus-in-primate-study 2025-03-18T07:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/654848c2697ed4ce/perspective-therapeutics-doses-first-patient-in-combination-therapy-trial-for-advanced-melanoma 2025-03-18T07:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/fb2288ddb324a110/xoma-royalty-expands-portfolio-to-over-120-assets-reports-financial-results-for-2024 2025-03-18T05:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/41b90153697621c9/prime-medicine-advances-gene-editing-program-for-alpha-1-antitrypsin-deficiency-with-72-correction-rate 2025-03-18T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ac010ec3fb27faf4/anixa-biosciences-to-present-novel-ovarian-cancer-car-t-therapy-data-at-asco-2025 2025-03-18T03:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/459cb0c1f4072c1d/sangamo-therapeutics-advances-neurology-pipeline-and-fabry-disease-gene-therapy-amid-financial-restructuring 2025-03-18T02:02:59+00:00 hourly 0.9 https://trial.medpath.com/news/2adf0ae845c5720e/tofersen-shows-promise-in-slowing-progression-of-sod1-motor-neuron-disease 2025-03-18T01:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/40d7b1ba2317da8e/fda-approves-alnylam-s-oxlumo-as-first-treatment-for-ultra-rare-kidney-disease-ph1 2025-03-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/78aca5de76ebb609/advancements-in-gene-therapy-approaches-for-neuromuscular-diseases-promises-and-challenges 2025-03-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8a93a2a9c466d26a/engineered-nasal-bacteria-successfully-deliver-obesity-drugs-to-brain-bypassing-blood-brain-barrier 2025-03-17T22:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/4c282f411ce46b7b/egle-therapeutics-secures-eur9-3-million-in-french-government-funding-to-advance-treg-targeting-cancer-therapies 2025-03-17T22:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/5d747f74b7b98ce2/eteplirsen-shows-dual-benefits-in-duchenne-muscular-dystrophy-slowing-cardiac-decline-and-delaying-loss-of-ambulation 2025-03-17T22:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/225845ebc342ea6f/incyte-s-povorcitinib-phase-3-trial-results-disappoint-investors-despite-meeting-primary-endpoints 2025-03-17T22:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/a1b16558e5f11290/new-ai-powered-line-clearance-solution-promises-85-time-savings-for-pharmaceutical-manufacturing 2025-03-17T20:02:22+00:00 hourly 0.9 https://trial.medpath.com/news/acde05221141ff4c/atezolizumab-plus-chemotherapy-shows-promising-results-for-advanced-thymic-carcinoma 2025-03-17T19:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/e6a5497e52b59130/savara-to-present-phase-3-impala-2-trial-data-on-molgramostim-for-rare-lung-disease-at-multiple-international-conferences 2025-03-17T19:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/90b8a01dac62e971/vertanical-achieves-phase-3-success-with-novel-non-opioid-pain-medication 2025-03-17T19:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/8fee90264b1cf06b/astrazeneca-partners-with-alteogen-to-develop-subcutaneous-oncology-treatments-using-novel-hyaluronidase-technology 2025-03-17T19:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/e8dcbf8a1ab5a384/fda-grants-orphan-drug-designation-to-bioarctic-s-exidavnemab-for-multiple-system-atrophy 2025-03-17T19:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/81cf1cd054572d9c/curevo-secures-110-million-series-b-funding-to-advance-next-generation-shingles-vaccine 2025-03-17T17:03:28+00:00 hourly 0.9 https://trial.medpath.com/news/bec222e11f303527/dyne-s-dyne-251-shows-unprecedented-functional-improvements-in-duchenne-muscular-dystrophy-trial 2025-03-17T16:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/5c4fb9887717fd8b/filament-health-s-botanical-psilocybin-shows-promise-in-reducing-alcohol-consumption-in-phase-2-trial 2025-03-17T16:39:35+00:00 hourly 0.9 https://trial.medpath.com/news/aa306d9783e0cf53/fda-clears-rona-therapeutics-ind-for-phase-2-study-of-rn0361-in-hypertriglyceridemia 2025-03-17T16:39:34+00:00 hourly 0.9 https://trial.medpath.com/news/2e4175ebbb7eabda/marvel-biosciences-to-seek-orphan-drug-designation-for-novel-rett-syndrome-treatment 2025-03-17T16:38:59+00:00 hourly 0.9 https://trial.medpath.com/news/32e325fa3cae209a/fda-grants-fast-track-designation-to-cellphire-s-clph-511-for-acute-hemorrhage-treatment 2025-03-17T16:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/c46d74a7a9da6832/biotech-ipo-market-faces-extended-slump-through-2026-amid-regulatory-uncertainty-and-poor-returns 2025-03-17T16:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/6b83d9128620f397/tempus-ai-strengthens-precision-medicine-platform-with-strategic-deep-6-ai-acquisition 2025-03-17T16:37:22+00:00 hourly 0.9 https://trial.medpath.com/news/88116b72f585a3b2/fortress-biotech-and-partex-form-strategic-ai-partnership-to-accelerate-drug-discovery-and-development 2025-03-17T16:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/958668f9289f4468/astrazeneca-acquires-european-cell-therapy-biotech-in-deal-worth-up-to-1-billion 2025-03-17T16:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/c110d11097d1dcd4/perimeter-medical-submits-fda-premarket-approval-for-ai-enabled-oct-system-in-breast-cancer-surgery 2025-03-17T16:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/d20bf9d566a48f27/opthea-s-clinical-trial-failure-threatens-company-survival-and-impacts-regal-partners 2025-03-17T16:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/1f888447ff694af7/springbok-analytics-pioneers-ai-driven-mri-analysis-in-landmark-pediatric-fshd-study 2025-03-17T16:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/9335f7808976522e/nih-launches-first-human-trial-of-lassarab-vaccine-for-deadly-lassa-fever 2025-03-17T16:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/c9c0afafa00da628/qxo-secures-830-million-in-private-placement-and-prices-500-million-common-stock-offering-for-beacon-acquisition 2025-03-17T16:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/9b78041d2cae8d60/cytokinetics-to-present-new-aficamten-data-at-acc-2025-insights-on-metabolism-combination-therapy-and-long-term-cardiac-effects 2025-03-17T14:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/e99dae3de3aca7ce/astrazeneca-acquires-esobiotec-for-up-to-1-billion-to-transform-cancer-cell-therapy 2025-03-17T14:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/ece45a7a55765590/prokidney-reports-positive-progress-in-rilparencel-development-for-advanced-ckd 2025-03-17T13:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/fcca03c8a4b0dc7c/asimov-expands-strategic-partnerships-to-accelerate-biologics-development-through-cho-edge-platform 2025-03-17T13:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/b9664d25dd536dc8/chance-pharma-secures-new-funding-to-advance-phase-iii-trials-of-innovative-inhalation-therapy 2025-03-17T13:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/9bf8a52c9939b61e/oncimmune-enters-administration-after-failed-sale-attempts-and-funding-shortfall 2025-03-17T13:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/5d0cfd007ac7743c/cidara-s-cd388-shows-promise-as-universal-influenza-preventative-in-nature-microbiology-publication 2025-03-17T13:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/61d3bc4a302e204f/mindmed-appoints-matt-wiley-as-chief-commercial-officer-to-lead-mm120-launch-strategy 2025-03-17T13:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/f4e2bdd8f1bb6a9c/fda-approves-xeris-biopharma-s-gvoke-vialdx-as-first-ready-to-dilute-liquid-glucagon-for-gastrointestinal-diagnostics 2025-03-17T13:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/43954e943230f8a6/avenacy-expands-injectable-antibiotic-portfolio-with-launch-of-five-critical-products-in-u-s-market 2025-03-17T13:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/41808003e036413c/taiho-pharmaceutical-to-acquire-swiss-adc-pioneer-araris-biotech-for-up-to-1-14-billion 2025-03-17T13:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/67ed7e3f861c2c2c/anocca-secures-regulatory-approval-for-first-in-human-pancreatic-cancer-trial-using-novel-tcr-t-cell-therapy 2025-03-17T13:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/6afb49c036b05d20/solascure-initiates-new-phase-ii-trial-for-aurase-wound-gel-in-chronic-wound-treatment 2025-03-17T13:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/da8bce0b045b49e2/incyte-s-povorcitinib-shows-significant-efficacy-in-phase-3-trials-for-hidradenitis-suppurativa 2025-03-17T13:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/67eb1e76bf115fbe/archer-platform-launches-at-cambridge-university-hospitals-to-revolutionize-clinical-trial-data-management 2025-03-17T13:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/855ffe688eb9d0f2/opko-health-and-entera-bio-collaborate-to-develop-first-oral-glp-1-glucagon-dual-agonist-for-obesity-treatment 2025-03-17T13:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/4b845bff4b018c24/fda-lifts-clinical-hold-on-vtv-therapeutics-cadisegliatin-for-type-1-diabetes 2025-03-17T13:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/adbea4472cddd5ca/regeneron-s-linvoseltamab-shows-promising-results-in-phase-1b-trial-for-multiple-myeloma 2025-03-17T13:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/dc292af42d1e62f3/atai-life-sciences-advances-psychedelic-therapy-pipeline-with-key-clinical-milestones-and-extended-financial-runway 2025-03-17T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/f79a1d81036aef61/astrazeneca-s-eneboparatide-meets-primary-endpoint-in-phase-iii-trial-for-hypoparathyroidism 2025-03-17T10:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/10f57cec777a9b92/maxion-therapeutics-secures-72m-series-a-to-advance-novel-knotbody-platform-for-ion-channel-diseases 2025-03-17T10:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/e16e53c845e470d5/peptris-technologies-licenses-india-s-first-ai-discovered-drug-candidate-for-duchenne-muscular-dystrophy 2025-03-17T10:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/2efc70152987fb94/latigo-secures-150m-series-b-to-advance-non-opioid-pain-medications-through-late-stage-trials 2025-03-17T10:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/19a7101420f57818/european-commission-approves-bms-s-breyanzi-for-relapsed-or-refractory-follicular-lymphoma 2025-03-17T10:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/9a8dfb9183dc9700/pacylex-initiates-phase-1-2-trial-of-first-in-class-n-myristoyltransferase-inhibitor-zelenirstat-in-relapsed-refractory-aml 2025-03-17T09:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/168ad539f961ac9a/roche-enters-obesity-market-with-major-deal-as-j-j-abandons-next-gen-darzalex-development 2025-03-17T07:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/668fd0fe5386a4d6/biophytis-bio101-shows-promising-phase-ii-results-in-sarcopenia-treatment-advancing-to-phase-iii 2025-03-17T07:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/f3e958e356d281ca/breakthrough-chinese-cancer-therapy-uses-modified-viruses-to-transform-tumors-into-foreign-tissue 2025-03-17T07:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/3e10b67b509c989c/ms-20-shows-remarkable-efficacy-as-add-on-therapy-for-ulcerative-colitis-in-clinical-trial 2025-03-17T07:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/b4661a4ff431fb53/avance-clinical-expands-asia-pacific-footprint-with-four-strategic-partnerships-in-taiwan 2025-03-17T02:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/ef72f82572c2eaf8/retinalogik-secures-1-1m-funding-and-health-canada-approval-for-vr-ai-eye-care-platform 2025-03-17T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7f8d695fc9535544/esr1-mutations-in-breast-cancer-emerging-biomarker-reshapes-treatment-strategies 2025-03-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/936b652620ce63e5/fda-removes-rems-requirement-for-tryvio-simplifying-access-to-novel-hypertension-treatment 2025-03-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4d0bdb7bd5316073/cepi-awards-5-million-to-nagasaki-university-for-revolutionary-nanoball-mrna-vaccine-platform 2025-03-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e83fccb95564dbeb/benralizumab-shows-superior-long-term-outcomes-in-eosinophilic-granulomatosis-with-polyangiitis 2025-03-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7ff9919d8922833e/sarepta-s-gene-therapy-for-limb-girdle-muscular-dystrophy-shows-sustained-5-year-safety-profile 2025-03-16T22:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/d7eb7810b1cd469a/puxitatug-samrotecan-shows-promise-in-advanced-endometrial-cancer-with-38-response-rate 2025-03-16T22:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/b9bb5f2304425adf/luveltamab-tazevibulin-shows-promising-results-in-platinum-resistant-ovarian-cancer-with-low-to-high-fra-expression 2025-03-16T19:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/bc7ea45d5bf4c8bb/allchem-lifescience-files-for-ipo-to-raise-190-crore-expands-api-manufacturing-capabilities 2025-03-16T19:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/57355c58b76f714c/hiv-drug-efavirenz-shows-promise-as-potential-chikungunya-treatment-in-iit-roorkee-study 2025-03-16T19:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/f55091d2a4cf3ca4/nhs-launches-ps10-million-clinical-trial-on-puberty-blockers-following-cass-review-recommendations 2025-03-16T19:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/ba7a63f068f66994/singapore-launches-first-covid-19-human-challenge-trial-with-five-volunteers 2025-03-16T19:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/ba4249f1c4ddc6b8/digital-innovation-a-lifeline-for-rare-disease-drug-development-and-patient-care 2025-03-16T17:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/04d6636242d4665f/grifols-immunoglobulin-therapy-shows-promising-results-in-post-polio-syndrome-clinical-trial 2025-03-16T16:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/37de6abd0de7af82/insilico-medicine-secures-110m-series-e-funding-achieves-unicorn-status-for-ai-driven-drug-discovery 2025-03-16T01:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/4a2b3bf2652d3454/sutro-biopharma-faces-multiple-downgrades-after-discontinuing-lead-program-luvelta 2025-03-16T01:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/333061d073021362/sutro-biopharma-reports-promising-results-for-luvelta-in-platinum-resistant-ovarian-cancer-trial 2025-03-16T01:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/7e82a6b2d2236e26/zimberelimab-plus-lenvatinib-shows-promise-in-advanced-cervical-cancer-after-ici-failure 2025-03-15T22:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/24028a756f2ccc85/afuresertib-plus-paclitaxel-fails-to-improve-survival-in-platinum-resistant-ovarian-cancer-trial 2025-03-15T22:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/8d8a362afad4c491/cdsco-panel-recommends-protocol-revisions-for-zydus-healthcare-s-empagliflozin-metoprolol-combination-therapy 2025-03-15T19:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/47787d72984915bd/olaparib-durvalumab-combination-shows-broad-pfs-benefits-across-pmmr-endometrial-cancer-subgroups 2025-03-15T19:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/4ea84390d3b123d3/cadonilimab-plus-lenvatinib-shows-promise-in-advanced-endometrial-cancer-after-platinum-failure 2025-03-15T19:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/9da6fb3747b930de/benuvia-operations-secures-anvisa-gmp-certification-expanding-pharmaceutical-manufacturing-capabilities-in-brazil 2025-03-15T16:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/a6e7d9a915f3fc11/nivolumab-shows-promising-results-in-dmmr-msi-h-endometrial-cancer-potentially-eliminating-need-for-surgery 2025-03-15T16:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/be95dcd9542e4abd/elahere-shows-32-reduction-in-death-risk-for-platinum-resistant-ovarian-cancer-in-final-mirasol-trial-analysis 2025-03-15T13:36:56+00:00 hourly 0.9 https://trial.medpath.com/news/48e8598730ff563e/ioncologi-acquires-targimmune-therapeutics-to-advance-novel-immunotherapies-for-solid-tumors 2025-03-15T13:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/c59f4bf31ee38cb2/alpha-teknova-and-pluristyx-partner-to-advance-allogeneic-cell-therapy-manufacturing-with-novel-cryopreservation-system 2025-03-15T13:36:54+00:00 hourly 0.9 https://trial.medpath.com/news/277185e23b5826f7/willow-biosciences-sells-operating-subsidiary-for-us-3-38-million-in-strategic-divestiture 2025-03-15T13:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/cf43f2bd3304a182/optimizing-treatment-strategies-for-relapsed-multiple-myeloma-from-car-t-cell-therapy-to-novel-combinations 2025-03-15T05:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/77750fa57f88eb33/five-years-later-covid-19-s-lasting-impact-on-oncology-care-and-research 2025-03-15T02:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/aac95f67ec3f12ef/uk-government-maintains-high-pharmaceutical-rebate-rates-despite-industry-pushback 2025-03-15T02:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/236c3b90d59ea1fe/ilet-bionic-pancreas-shows-equal-efficacy-in-primary-care-and-specialty-settings-for-type-1-diabetes 2025-03-15T01:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/c3a78c4a918b2be7/india-launches-5000-crore-pharma-r-d-fund-to-boost-innovation-and-reduce-import-dependence 2025-03-15T01:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/29b4c3fdbe4db184/latigo-secures-150m-funding-to-advance-non-opioid-pain-treatment-in-competition-with-vertex 2025-03-15T01:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/9c6b3fad197a7ddb/biogen-s-felzartamab-shows-promising-results-in-iga-nephropathy-phase-2-trial 2025-03-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4f53b75d73aa5485/hu6-shows-promise-in-treating-obesity-related-heart-failure-by-reducing-body-fat-while-preserving-muscle-mass 2025-03-14T23:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/2908bdb659c4e76c/syngene-international-expands-global-footprint-with-50-million-us-biologics-facility-acquisition 2025-03-14T22:04:39+00:00 hourly 0.9 https://trial.medpath.com/news/55cdde36f6589b6c/moscow-s-pharmaceutical-sector-expands-with-37-new-medicines-and-monoclonal-antibody-production 2025-03-14T22:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/5b2616532698ce10/exopten-shows-promising-results-for-spinal-cord-injury-recovery-in-preclinical-study 2025-03-14T22:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/c886429aaa6f5187/first-in-human-trial-tests-herpes-virus-based-gene-therapy-for-neurogenic-bladder-in-spinal-cord-injury-patients 2025-03-14T22:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/e97656e0e47bd976/samsung-invests-10-million-in-c2n-diagnostics-to-advance-brain-health-diagnostics 2025-03-14T19:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/24e930d7dac26824/sanofi-accelerates-flu-vaccine-production-for-2025-26-season-amid-severe-current-outbreak 2025-03-14T19:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/b6034e874dc15ee5/altimmune-expands-pemvidutide-testing-to-alcohol-use-disorder-and-liver-disease 2025-03-14T19:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/2aabce7f18d5586e/accropeutics-secures-12-million-series-b-financing-to-advance-novel-therapeutics-for-immune-mediated-diseases 2025-03-14T19:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/5ea08576ea634171/circulating-dna-rna-market-set-to-triple-to-16-4-billion-by-2032-driven-by-patent-innovations 2025-03-14T19:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/9382d43d307cbef8/fda-approves-ostiserene-new-single-dose-treatment-for-canine-otitis-externa 2025-03-14T19:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/c0c132beb2fd94cb/meta-analysis-confirms-sacituzumab-govitecan-s-superior-efficacy-in-hr-her2-metastatic-breast-cancer 2025-03-14T19:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/c56cde4b32a6d46a/weight-loss-drugs-wegovy-and-zepbound-not-cost-effective-at-current-prices-study-finds 2025-03-14T19:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/c24199eada39bf0a/fibrobiologics-partners-with-charles-river-to-advance-fibroblast-based-therapy-for-diabetic-foot-ulcers 2025-03-14T19:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/a75ccc3e20c196a5/mainehealth-launches-nih-funded-clinical-trials-to-address-long-covid-symptoms 2025-03-14T19:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/70501cd15ee47172/surf-bio-strengthens-leadership-team-with-cmc-expert-doug-hecker-to-advance-subcutaneous-biologic-delivery-platform 2025-03-14T16:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/a9797125a8d6b847/biolexis-therapeutics-confirms-novel-allosteric-mechanism-for-oral-glp-1-receptor-agonist 2025-03-14T16:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/c4c8f28153f81dcb/fda-clears-j-j-s-ai-enhanced-monarch-robot-for-improved-lung-cancer-diagnosis 2025-03-14T16:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/def8e6f64fc4bc72/ema-recommends-first-vaccine-against-epizootic-haemorrhagic-disease-for-cattle-in-eu 2025-03-14T16:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/395a7df81404440b/dupilumab-shows-promise-in-reducing-ige-levels-in-food-allergy-patients 2025-03-14T16:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/988f0d8277cd5d23/neuraceq-r-pet-imaging-agent-to-launch-in-hong-kong-advancing-alzheimer-s-diagnosis-capabilities 2025-03-14T16:32:41+00:00 hourly 0.9 https://trial.medpath.com/news/058fb31135da2956/hkust-and-siic-launch-hk-600-million-biotechnology-fund-to-accelerate-healthcare-innovation 2025-03-14T16:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/65fcf8199df9f74c/panthera-biopartners-secures-ps20m-in-clinical-trial-contracts-amid-uk-smo-sector-growth 2025-03-14T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/e48faad19daff89c/autonomix-medical-completes-integration-of-apex-6-generator-advancing-toward-2025-clinical-trials-for-pancreatic-cancer-pain 2025-03-14T16:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/d313010ebb31fecf/splicebio-initiates-first-in-human-trial-of-dual-aav-gene-therapy-for-stargardt-disease 2025-03-14T13:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/7c5abe5beca7c686/fda-approves-iluvien-label-expansion-for-chronic-non-infectious-uveitis-treatment 2025-03-14T13:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/e7e413f69a4ccc58/eton-pharmaceuticals-et-600-meets-bioequivalence-endpoints-for-central-diabetes-insipidus-treatment 2025-03-14T13:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/c6d1fe9dc22e8724/china-approves-sycume-r-first-igf-1r-antibody-for-thyroid-eye-disease-in-70-years 2025-03-14T10:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/79bd568b93d52102/uk-government-commits-ps121-million-to-revitalize-clinical-trial-sector-following-o-shaughnessy-review 2025-03-14T08:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/47cb5dce79a4071f/antibody-drug-conjugates-revolutionize-treatment-landscape-for-metastatic-breast-cancer 2025-03-14T07:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/1022d8894b425cb8/bostongene-wins-two-major-awards-for-ai-driven-cancer-diagnostics-and-immunology-solutions 2025-03-14T03:02:01+00:00 hourly 0.9 https://trial.medpath.com/news/89e631dbd4802fc3/inovio-s-dna-encoded-monoclonal-antibodies-show-durable-72-week-expression-without-immune-rejection-in-covid-19-trial 2025-03-14T01:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/fb32150fcad1b1ab/bayer-and-crispr-therapeutics-form-300-million-joint-venture-to-advance-gene-editing-therapies 2025-03-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d6f10c2b26b2702f/telix-pharmaceuticals-expands-radiopharmaceutical-portfolio-with-strategic-fap-targeting-acquisition 2025-03-13T19:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/f69ad77fc832bfdf/vivani-medical-achieves-first-glp-1-implant-and-full-enrollment-in-liberate-1-trial-for-obesity-treatment 2025-03-13T19:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/0273b83c06757d31/heidelberg-pharma-secures-20-million-in-amended-royalty-deal-with-healthcare-royalty-for-renal-cancer-diagnostic 2025-03-13T17:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/a036b726452cc4a7/genfit-secures-eur185-million-royalty-financing-deal-with-hcrx-restructures-convertible-debt 2025-03-13T16:38:26+00:00 hourly 0.9 https://trial.medpath.com/news/70c6460550cac980/faeth-therapeutics-advances-novel-three-pronged-approach-for-metabolism-driven-cancers-with-promising-preclinical-results 2025-03-13T16:37:08+00:00 hourly 0.9 https://trial.medpath.com/news/0632b744850d9e04/stealth-biotherapeutics-reaches-50-enrollment-milestone-in-phase-3-trial-for-novel-dry-amd-treatment 2025-03-13T16:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/37292b0a96208a5a/amgen-s-uplizna-shows-sustained-efficacy-in-myasthenia-gravis-patients-through-one-year 2025-03-13T16:36:20+00:00 hourly 0.9 https://trial.medpath.com/news/23ab8f2646038123/helix-research-network-reveals-genomic-screening-improves-patient-care-and-risk-identification-at-acmg-2025 2025-03-13T16:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/e4fe115bbd30d1ca/immunoprecise-antibodies-secures-10m-partnership-for-ai-driven-cancer-therapeutics-development 2025-03-13T16:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/e47f142cce5c6820/amgen-and-fresenius-kabi-reach-settlement-in-denosumab-biosimilar-litigation 2025-03-13T16:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/177c444f51fbeae5/immorta-bio-s-senovax-shows-tumor-regression-across-multiple-cancer-types-in-preclinical-studies 2025-03-13T16:35:27+00:00 hourly 0.9 https://trial.medpath.com/news/9902859b35a2e3e9/dyne-therapeutics-dyne-101-shows-promise-for-accelerated-approval-pathway-in-dm1 2025-03-13T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/709ad1e86d067f4c/fda-clears-spineart-s-perla-r-app-for-use-with-ecential-robotics-op-ntm-navigation-platform 2025-03-13T16:33:25+00:00 hourly 0.9 https://trial.medpath.com/news/63cd1b1588c9ce90/fda-grants-510-k-clearance-for-rewalk-7-exoskeleton-for-spinal-cord-injury-patients 2025-03-13T16:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/ba64c4caf9204b9f/senate-confirms-makary-and-bhattacharya-to-lead-fda-and-nih-amid-healthcare-reform-push 2025-03-13T16:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/5f38c440220aab19/cosciens-biopharma-advances-oat-derived-anti-inflammatory-compound-to-phase-2a-following-successful-safety-trial 2025-03-13T16:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/e17db25d39d37455/exicure-secures-australian-patent-for-novel-cancer-treatment-targeting-cxcr4-and-gpcrx 2025-03-13T15:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/f6940a9dc753c7d6/mainz-biomed-and-liquid-biosciences-develop-breakthrough-blood-test-for-pancreatic-cancer-detection 2025-03-13T14:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/535074d4900a2a00/major-insulin-manufacturers-agree-to-35-monthly-price-caps-in-state-settlements 2025-03-13T14:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/cec15ef1c7b813ba/mallinckrodt-and-endo-to-merge-in-6-7b-deal-creating-pharmaceutical-powerhouse 2025-03-13T14:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/6f478449e3ce39fb/meiragtx-and-hologen-ai-form-430-million-strategic-collaboration-to-advance-parkinson-s-disease-gene-therapy 2025-03-13T14:02:32+00:00 hourly 0.9 https://trial.medpath.com/news/53fe90c97a9d7f0c/fuse-oncology-and-acro-forge-strategic-partnership-to-standardize-radiation-oncology-clinical-pathways 2025-03-13T13:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/8bcda919890d030a/fda-clears-pds-biotech-s-novel-immunotherapy-combination-for-metastatic-colorectal-cancer-trial 2025-03-13T13:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/0270d43487a23ae7/fda-clears-phase-2-trial-of-tpst-1495-for-familial-adenomatous-polyposis-treatment 2025-03-13T13:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/f232bde60de70e53/new-york-man-becomes-first-in-state-to-be-cured-of-sickle-cell-disease-with-lyfgenia-gene-therapy 2025-03-13T13:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/a72108269580b1ac/hypersomnia-pipeline-shows-promise-with-10-emerging-therapies-in-development 2025-03-13T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/bade7e10a8c9c259/european-commission-approves-rxulti-for-adolescent-schizophrenia-treatment 2025-03-13T13:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/a89f815e8534d1a5/uflex-secures-fda-approval-for-recycled-polyethylene-in-food-packaging-a-first-for-indian-companies 2025-03-13T13:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/0864433f5c55d04d/fda-approves-early-feasibility-study-for-valcare-medical-s-amend-trans-septal-system-for-mitral-regurgitation 2025-03-13T13:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/d1eadd6ef49c7689/proqr-advances-rna-editing-pipeline-with-four-clinical-readouts-expected-by-2026 2025-03-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9b2a79532718b156/proteomics-international-launches-promarkerd-revolutionary-predictive-test-for-diabetic-kidney-disease-in-australia 2025-03-13T11:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/0ce25b061006f28f/perfuze-secures-fda-clearance-for-zipline-access-catheters-and-eur22m-funding-for-stroke-treatment-innovation 2025-03-13T11:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/75d0ad1ba922d403/new-endometriosis-pill-ryeqo-approved-for-nhs-use-offering-hope-to-1-5-million-uk-sufferers 2025-03-13T10:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/b14533dd9a288e06/fda-delays-approval-of-eli-lilly-s-alzheimer-s-drug-donanemab-requests-additional-safety-data 2025-03-13T10:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/94e6a42337d6dbc9/arpis-show-similar-efficacy-in-mhspc-regardless-of-disease-volume-drug-selection-should-focus-on-patient-specific-factors 2025-03-13T10:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/177a25eae405128e/pranax-secures-md-anderson-exosome-technology-license-for-regenerative-medicine-applications 2025-03-13T10:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/7f869b9fe526f9f4/paragonix-secures-eu-mdr-approval-for-five-organ-preservation-devices-expanding-european-market-access 2025-03-13T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/42bebefa21da438d/ennodc-s-antibody-mediated-vaccines-show-promising-long-term-immunity-in-hiv-phase-i-trial 2025-03-13T09:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/205e012eb4c24abd/first-hormone-free-male-birth-control-pill-shows-99-efficacy-in-preclinical-studies 2025-03-13T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/e90ba22d1e7a3e06/kane-biotech-advances-novel-dispersinb-r-acne-treatment-with-irb-approval-for-clinical-trial 2025-03-13T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/9a551fe2c4c3da22/st-vincent-s-melbourne-and-cmuh-forge-international-partnerships-to-advance-clinical-research 2025-03-13T07:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/61a05f0c03bac9e6/fda-accepts-merck-s-application-for-novel-two-drug-hiv-regimen-doravirine-islatravir 2025-03-13T07:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/cd8df5fab5b5e042/fda-clears-cero-therapeutics-ind-for-novel-car-t-therapy-cer-1236-in-solid-tumors 2025-03-13T07:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/a8668ea29f91365b/neurogen-biomarking-partners-with-neurox-to-revolutionize-early-alzheimer-s-detection 2025-03-13T07:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/865a79b671c8c248/emergent-biosolutions-invests-in-rocketvax-to-advance-next-generation-vaccine-development 2025-03-13T05:01:57+00:00 hourly 0.9 https://trial.medpath.com/news/67a494f860eaf42e/florida-clinical-trial-facility-owners-plead-guilty-to-falsifying-asthma-drug-study-data 2025-03-13T04:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/b47ae87bde43108e/neural-therapeutics-advances-ethnobotanical-drug-discovery-platform-for-substance-use-disorders 2025-03-13T04:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/6180330d2019fb18/third-arc-bio-initiates-phase-1-trial-of-novel-t-cell-engager-arc101-for-cldn6-positive-cancers 2025-03-13T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e4b5afa82a8c9579/nrx-pharmaceuticals-advances-nmda-platform-with-breakthrough-therapies-for-suicidal-depression-and-chronic-pain 2025-03-13T03:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/6972c388539c7dce/significant-gaps-in-hiv-care-for-children-and-adolescents-require-urgent-attention 2025-03-13T02:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/8765db02dc5b2ce3/donanemab-treatment-for-alzheimer-s-disease-linked-to-significant-aria-risk-analysis-reveals 2025-03-13T01:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/72b9d22c456e8061/muscular-dystrophy-research-reaches-turning-point-regeneration-emerges-as-next-frontier 2025-03-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0fd4d09034f22e77/gsk-s-blenrep-secures-uk-approval-for-multiple-myeloma-treatment-in-combination-therapy 2025-03-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/be707ebd0bedf7a4/viiv-healthcare-s-mid-stage-study-demonstrates-robust-hiv-viral-suppression-with-long-acting-therapy 2025-03-12T23:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/f7a611295bb0d9d1/actinium-pharmaceuticals-initiates-novel-triplet-therapy-trial-for-frontline-aml-treatment 2025-03-12T22:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/7c26226b2d77dad1/bloom-science-and-ascletis-report-promising-results-in-obesity-treatment-trials 2025-03-12T20:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/b8ca963debe404eb/vivani-medical-to-spin-off-cortigent-neurostimulation-business-as-independent-public-company 2025-03-12T20:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/50348997c3c1ddbf/dogwood-therapeutics-converts-19-5m-debt-to-equity-advances-phase-2b-trial-of-non-opioid-pain-treatment 2025-03-12T20:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/6a84965875e856b6/urogen-s-ugn-102-nears-fda-approval-with-impressive-phase-3-results-for-bladder-cancer 2025-03-12T20:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/10a951fb865dbf66/nash-pipeline-shows-promise-with-80-emerging-therapies-in-development 2025-03-12T20:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/dee15433b6e5bfe6/pembrolizumab-addition-to-docetaxel-shows-no-benefit-in-metastatic-castration-resistant-prostate-cancer 2025-03-12T19:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/ac831497781ccfe5/ensitrelvir-shows-67-reduction-in-covid-19-risk-as-first-effective-post-exposure-prophylaxis-in-phase-3-trial 2025-03-12T19:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/765f2dd257760dda/new-antiviral-drug-ensitrelvir-shows-promise-in-preventing-covid-19-after-household-exposure 2025-03-12T19:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/1d2c4e1f0616180b/viiv-healthcare-s-n6ls-broadly-neutralizing-antibody-shows-promise-in-hiv-long-acting-treatment 2025-03-12T19:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/4b218db6b95173bc/seismic-therapeutic-advances-clinical-programs-with-dosing-of-healthy-subjects-in-two-phase-i-trials 2025-03-12T19:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/685a71a4d28d62ed/gc-cell-doses-first-patient-in-phase-1-trial-of-novel-cd5-car-nk-cell-therapy-for-t-cell-lymphoma 2025-03-12T19:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/83ec074d063e66cd/roche-expands-molecular-glue-portfolio-with-2-billion-monte-rosa-partnership 2025-03-12T17:02:10+00:00 hourly 0.9 https://trial.medpath.com/news/388568814bea4bb4/legend-biotech-reports-strong-carvykti-r-growth-with-963-million-in-2024-sales-treating-over-5000-patients 2025-03-12T16:36:39+00:00 hourly 0.9 https://trial.medpath.com/news/5412c0f77db450ea/shuttle-pharmaceuticals-secures-5-75-million-in-public-offering-to-advance-cancer-radiation-therapy-research 2025-03-12T16:36:12+00:00 hourly 0.9 https://trial.medpath.com/news/74b3d5afbc6f9d74/novel-nanogel-delivery-system-shows-promise-for-treating-recurrent-utis 2025-03-12T16:34:49+00:00 hourly 0.9 https://trial.medpath.com/news/e7c9c288cfb5ad20/lenacapavir-and-broadly-neutralizing-antibodies-show-promise-as-twice-yearly-hiv-treatment 2025-03-12T16:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/bbcc538db367eddc/bipolar-depression-market-set-to-grow-through-2034-with-new-therapies-in-pipeline 2025-03-12T16:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/606053ab42d6ee3e/repurposing-losartan-hypertension-drug-shows-promise-for-treating-epidermolysis-bullosa-in-children 2025-03-12T16:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/bdc92a433f1323eb/fda-approves-elute-s-bonvie-a-novel-resorbable-bone-void-filler-addressing-limitations-of-current-options 2025-03-12T16:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/0b10fbe2ab42c05c/cs-diagnostics-enlists-lachman-consultants-to-secure-fda-approval-for-novel-cancer-treatment-hydrogel 2025-03-12T16:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/65f903f927e3a98e/corvus-pharmaceuticals-initiates-phase-2-trial-of-soquelitinib-for-rare-genetic-disease-alps 2025-03-12T16:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/df6c34b4174f5a1e/ose-immunotherapeutics-reports-significant-survival-benefit-in-phase-ii-pancreatic-cancer-vaccine-trial 2025-03-12T16:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/eb205be8bb9d5c09/trial-library-and-aon-partner-to-enhance-cancer-clinical-trial-access-with-ai-enabled-matching-technology 2025-03-12T16:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/220d0fdcfb45fca2/science-translational-medicine-validates-efzofitimod-s-novel-mechanism-for-treating-lung-inflammation 2025-03-12T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ee4051a2c61a66f5/blood-test-monitoring-pd-l1-expression-shows-promise-for-improving-immunotherapy-outcomes-in-metastatic-breast-cancer 2025-03-12T15:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/ba342f0b7b6326ee/mineralys-therapeutics-secures-175-million-in-public-offering-to-advance-aldosterone-inhibitor-for-cardiorenal-diseases 2025-03-12T14:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/659f907f2ff3857f/quralis-reports-promising-phase-1-data-for-qrl-101-in-als-and-epilepsy-biomarker-study 2025-03-12T13:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/c4d3d1aeeccb49b9/glenmark-expands-diabetes-care-portfolio-with-launch-of-empagliflozin-and-fixed-dose-combinations-in-india 2025-03-12T13:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/ba482d2a69324b05/redhill-biopharma-to-launch-first-ever-clinical-trial-targeting-map-infection-in-crohn-s-disease 2025-03-12T13:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/19fa910d4bc02370/gates-foundation-funds-likarda-s-novel-antibody-secreting-cell-therapy-for-infectious-diseases 2025-03-12T12:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/e54b8a7653103bff/morning-asthma-testing-yields-more-reliable-results-study-reveals-significant-seasonal-variations 2025-03-12T11:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/18480ef411c73df4/celltrion-s-infliximab-biosimilar-rebranded-as-remdantrytm-in-canada-ensuring-treatment-continuity 2025-03-12T11:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/ea6f3f7448231dcf/longeveron-s-laromestrocel-shows-promise-in-phase-2a-trial-for-mild-alzheimer-s-disease 2025-03-12T10:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/f72da55c93d3b85d/cantargia-initiates-first-clinical-trial-of-nadunolimab-for-aml-and-mds-treatment 2025-03-12T10:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/8b51c89e8579f9c2/cognixion-launches-clinical-trial-testing-ai-driven-brain-computer-interface-for-late-stage-als-communication 2025-03-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f35778a72e1a47a9/envoy-medical-secures-10-million-funding-to-advance-pivotal-trial-of-fully-implanted-cochlear-implant 2025-03-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/92362c5b3d6b9a44/australian-man-survives-100-days-with-bivacor-artificial-titanium-heart-in-groundbreaking-trial 2025-03-12T08:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/2d0587c2174987f8/takeda-achieves-diversity-milestone-in-phase-3-psoriasis-trial-with-zasocitinib 2025-03-12T07:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/207d1d8a19260a41/roche-and-zealand-pharma-forge-5-3-billion-partnership-to-develop-novel-obesity-treatments 2025-03-12T07:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/2429acbed9b4232c/rion-initiates-phase-1b-trial-of-exosome-therapy-pep-for-knee-osteoarthritis 2025-03-12T07:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/5c9193a2ab796080/delhi-high-court-upholds-strict-patent-amendment-rules-in-two-key-pharmaceutical-cases 2025-03-12T06:40:29+00:00 hourly 0.9 https://trial.medpath.com/news/c1ae530ebc416482/bristol-myers-squibb-acquires-2seventy-bio-for-286-million-to-gain-full-control-of-car-t-therapy-abecma 2025-03-12T05:02:10+00:00 hourly 0.9 https://trial.medpath.com/news/8ba32ca0f1a9addc/fda-approves-larger-vial-sizes-of-takeda-s-glassia-for-alpha-1-antitrypsin-deficiency 2025-03-12T04:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/dc713ebc7e4fec8a/north-carolina-teen-makes-history-as-first-to-receive-fda-approved-gene-therapy-for-sickle-cell-disease 2025-03-12T04:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/4bc88bb023009d1f/ionis-and-ono-forge-940-million-deal-for-sapablursen-in-polycythemia-vera-treatment 2025-03-12T01:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/01242f154fa17f41/colorado-advances-legislation-to-allow-fda-approved-psilocybin-medications 2025-03-12T01:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/70ba065d29ed1c0d/nice-unable-to-recommend-atezolizumab-for-untreated-nsclc-due-to-lack-of-submission 2025-03-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b0f32f51ca06199c/patent-strategies-for-glp-1-receptor-agonists-extending-drug-lifecycles-through-novel-applications 2025-03-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d67b97100dad1889/neuroone-accelerates-fda-submission-timeline-for-onerf-trigeminal-nerve-ablation-system 2025-03-11T22:33:40+00:00 hourly 0.9 https://trial.medpath.com/news/f76fe06265b3b565/ose2101-cancer-vaccine-shows-promising-results-in-phase-2-pancreatic-cancer-trial 2025-03-11T22:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/b11d89b3e4dcba7d/gilead-advances-once-yearly-lenacapavir-for-hiv-prevention-to-phase-iii-after-promising-phase-i-results 2025-03-11T22:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/b3ab798ffd622a96/tempus-ai-acquires-deep-6-ai-to-enhance-clinical-trial-matching-and-patient-care 2025-03-11T22:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/7b277da8207f7a30/harrow-secures-five-year-supply-agreement-for-triesence-r-and-initiates-development-of-next-generation-version 2025-03-11T19:33:46+00:00 hourly 0.9 https://trial.medpath.com/news/a841d415750df568/cms-grants-adlt-status-to-guardant-health-s-shield-blood-test-for-colorectal-cancer-screening 2025-03-11T19:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/26876207a8abe3fb/radiosa-trial-shows-adt-addition-to-sbrt-improves-progression-free-survival-in-oligorecurrent-prostate-cancer 2025-03-11T19:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/5ba4d06e16424b68/shilpa-medicare-unveils-innovative-hybrid-cdmo-model-at-dcat-2025 2025-03-11T19:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/02be8c5d4c89fa7e/merck-unveils-1b-vaccine-manufacturing-facility-in-north-carolina 2025-03-11T19:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/7fa4c42144f3fea4/labcorp-to-acquire-bioreference-health-s-oncology-testing-assets-in-225-million-deal 2025-03-11T19:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/f6b4335d73b5b6b3/modus-therapeutics-completes-enrollment-for-phase-i-sevuparin-trial-in-pediatric-severe-malaria 2025-03-11T19:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/9658c4583a2c491f/centerline-biomedical-receives-fda-510-k-clearance-for-expanded-iops-applications-in-neurovascular-procedures 2025-03-11T17:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/1a7722fdcf312ba6/chinese-scientists-develop-promising-nanovaccine-to-prevent-arterial-plaque-build-up 2025-03-11T17:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/bb8325f24dfbc7b1/seismic-therapeutic-advances-novel-igg-protease-s-1117-into-phase-1-clinical-trial-for-autoimmune-diseases 2025-03-11T17:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/99fe7b5ac065f825/nasal-septum-cartilage-shows-significant-promise-in-repairing-complex-knee-injuries 2025-03-11T17:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/cce0ccf7676348f4/aprea-therapeutics-advances-apr-1051-clinical-trial-with-first-hpv-head-and-neck-cancer-patient-dosed 2025-03-11T17:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/da8d7f20085300fc/boehringer-ingelheim-launches-one-medicine-platform-to-accelerate-drug-development 2025-03-11T17:02:45+00:00 hourly 0.9 https://trial.medpath.com/news/18c0ffb4a9a56808/biogen-initiates-phase-3-transcend-trial-of-felzartamab-for-late-antibody-mediated-kidney-transplant-rejection 2025-03-11T16:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/548fd8882693f900/right-brain-bio-partners-with-suven-pharmaceuticals-to-manufacture-disease-modifying-parkinson-s-drug-rb-190 2025-03-11T16:35:34+00:00 hourly 0.9 https://trial.medpath.com/news/9217356f3fde2d90/great-southern-copper-reports-high-grade-cu-ag-results-from-mostaza-mine-drilling 2025-03-11T16:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/aa9cb49060347ef7/phase-3-prostate-iq-trial-launches-to-reduce-hormone-therapy-burden-in-prostate-cancer-patients 2025-03-11T16:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/d1157f3e2b0ace35/tuhura-biosciences-appoints-former-j-j-oncology-executive-craig-tendler-to-board-of-directors 2025-03-11T16:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/3276296218f959ab/crispr-breakthrough-israeli-team-eliminates-50-of-head-and-neck-tumors-by-targeting-single-gene 2025-03-11T16:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/40a38179fb7904cf/protagonist-s-icotrokinra-shows-promising-results-in-ulcerative-colitis-and-psoriasis-trials 2025-03-11T16:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/984ba4fbd6325621/caredx-expands-allosure-testing-to-pediatric-heart-and-simultaneous-pancreas-kidney-transplant-patients 2025-03-11T16:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/0995e0cb96b3372e/3d-printing-revolutionizes-drug-delivery-systems-with-precision-and-personalization 2025-03-11T16:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/fdd77ee8b17276f9/elevatebio-and-aws-partner-to-revolutionize-crispr-gene-editing-through-generative-ai 2025-03-11T16:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/3d56474e8ad3bad0/kazakhstan-s-breakthrough-cancer-drug-shows-promise-in-clinical-trials-registration-expected-by-2025 2025-03-11T16:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/c2d56a698b72d400/hansa-biopharma-completes-enrollment-in-phase-3-study-of-imlifidase-for-highly-sensitized-kidney-transplant-patients 2025-03-11T16:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/b7a0107b31d2e1d3/fda-clears-larger-50mm-magdi-magnet-expanding-gt-metabolic-s-magnetic-surgery-capabilities 2025-03-11T16:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/51b1f526cbfd66dc/cdc-plans-major-study-on-vaccine-autism-connection-amid-measles-outbreak 2025-03-11T16:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/b3f6e11db321a9a3/fda-accepts-nda-for-sydnexis-syd-101-first-potential-pharmaceutical-treatment-for-pediatric-myopia 2025-03-11T16:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/052d6d083ae1c100/lindus-health-and-sooma-medical-launch-phase-3-trial-for-novel-brain-stimulation-device-to-treat-depression 2025-03-11T16:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/309a90bb566f89d2/volition-s-nu-q-r-cancer-test-shows-promise-in-lung-cancer-screening-and-pan-cancer-detection 2025-03-11T16:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/d6783d5a3de770cf/tenon-medical-secures-3-0-million-through-warrant-transaction-to-advance-si-joint-fusion-technology 2025-03-11T15:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/026d37c31cb5a465/olumiant-shows-promising-results-for-adolescents-with-alopecia-areata-in-new-study 2025-03-11T14:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/40011c82917a3098/johnson-johnson-declines-option-for-genmab-s-hexabody-cd38-despite-promising-clinical-data 2025-03-11T14:01:50+00:00 hourly 0.9 https://trial.medpath.com/news/a278c46dad9b7b84/ovid-therapeutics-advances-novel-neurological-drug-pipeline-with-key-clinical-milestones-expected-in-2025-2026 2025-03-11T13:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/8a899bb17f9e1211/non-cystic-fibrosis-bronchiectasis-market-expected-to-reach-usd-7-5-billion-by-2035-driven-by-novel-therapies 2025-03-11T13:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/3f5614b5e60e2b8e/fda-clears-caristo-s-ai-powered-cari-plaque-technology-for-early-heart-attack-prevention 2025-03-11T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/67541688ff74f4e2/adaptive-biotechnologies-enhances-clonoseq-assay-for-dlbcl-minimal-residual-disease-detection-with-7-fold-sensitivity-increase 2025-03-11T12:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/e6c4a96a291a6786/nih-to-sponsor-phase-1-trial-of-fzata-s-novel-oral-biologic-fz002-for-c-difficile-treatment 2025-03-11T11:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/f1e4bc1d4259af57/neogenomics-expands-northeast-presence-with-strategic-acquisition-of-pathline 2025-03-11T10:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/66cfc2be839b355d/vori-health-secures-53-million-series-b-to-transform-musculoskeletal-care-delivery 2025-03-11T09:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/58eedf5cc1466967/better-choice-company-expands-healthcare-portfolio-with-acquisition-of-choice-specialty-pharmacy 2025-03-11T09:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/3d276dbca43eb780/medera-completes-dosing-in-phase-1-2a-gene-therapy-trial-for-heart-failure-with-promising-early-results 2025-03-11T09:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/d4c7da1cce799721/tonix-pharmaceuticals-receives-mcdc-grant-to-advance-tnx-801-vaccine-against-smallpox-and-mpox 2025-03-11T08:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/f40ab7760b846fea/navigating-the-orphan-drug-landscape-in-europe-hta-challenges-and-the-rising-role-of-real-world-evidence 2025-03-11T08:01:47+00:00 hourly 0.9 https://trial.medpath.com/news/2594d6d385f267b6/fda-clears-ind-for-sagimet-s-novel-fasn-inhibitor-tvb-3567-for-acne-treatment 2025-03-11T07:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/f79439f6ea99438e/knight-therapeutics-to-acquire-paladin-in-120-million-strategic-pharmaceutical-deal 2025-03-11T06:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/20fa4d9bd6b35c05/resistance-training-emerges-as-most-effective-exercise-for-insomnia-in-older-adults 2025-03-11T06:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/31298ddd99f8cde3/halia-therapeutics-secures-novo-nordisk-golden-ticket-for-innovative-obesity-and-inflammation-research 2025-03-11T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/52442b2d1a60c884/leukocyte-count-emerges-as-predictor-for-long-covid-severity-in-postmenopausal-women 2025-03-11T03:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/17e01d36a2811836/tevogen-bio-files-patent-for-novel-t-cell-vaccine-targeting-entire-viral-genomes 2025-03-11T02:01:55+00:00 hourly 0.9 https://trial.medpath.com/news/00d74de5fd4469b8/spineart-s-baguera-r-c-cervical-disc-prosthesis-meets-non-inferiority-thresholds-in-both-1-level-and-2-level-ide-studies 2025-03-11T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/356f80f33ac91c98/scotland-approves-new-cancer-treatments-for-prostate-and-liver-cancers 2025-03-11T01:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/e7d340219bb5819c/eli-lilly-s-orforglipron-daily-weight-loss-pill-shows-promise-in-phase-3-trial-for-obesity-and-diabetes 2025-03-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/72a840cad328739c/novel-pet-radiotracer-68ga-fz-nr-1-successfully-identifies-nectin-4-biomarker-in-triple-negative-breast-cancer-patients 2025-03-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/92a45afba0e14052/jak-inhibitors-reduce-thromboembolic-risk-in-myeloproliferative-neoplasms-through-novel-mechanisms 2025-03-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/795a0ffae0d63f8e/federal-circuit-ruling-on-immunogen-s-dosing-patent-highlights-challenges-in-pharmaceutical-patent-strategy 2025-03-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/409905751ffeb50a/vaccinex-to-delist-from-nasdaq-despite-promising-alzheimer-s-drug-results 2025-03-10T23:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/73e171fc8e34569c/moderna-and-pfizer-biontech-locked-in-escalating-mrna-patent-battle-with-billions-at-stake 2025-03-10T23:02:14+00:00 hourly 0.9 https://trial.medpath.com/news/77a62937c6228c0a/beam-therapeutics-achieves-breakthrough-in-base-editing-for-alpha-1-antitrypsin-deficiency 2025-03-10T22:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/4d850578ae08ab34/noramco-group-invests-25-million-to-establish-sterile-injectable-manufacturing-in-new-jersey 2025-03-10T22:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/30214de5d93a30df/kodiak-sciences-completes-enrollment-in-glow2-phase-3-trial-for-diabetic-retinopathy-treatment 2025-03-10T22:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/2eaa0590e8b8cb7d/beam-therapeutics-secures-500-million-in-public-offering-to-advance-base-editing-pipeline 2025-03-10T20:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/6d6f39dd925ca9e2/roche-s-piasky-becomes-first-subcutaneous-pnh-therapy-approved-in-eu 2025-03-10T20:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/b8930780a801e536/on-demand-manufacturing-emerges-as-solution-for-adaptive-clinical-trial-challenges-in-small-pharma 2025-03-10T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d07128be84263d44/msinsight-secures-eur1-6-million-seed-funding-to-transform-msi-cancer-diagnostics 2025-03-10T19:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/d68da7fde2c9d66b/donanemab-alzheimer-s-drug-shows-promise-but-raises-serious-safety-concerns 2025-03-10T19:06:22+00:00 hourly 0.9 https://trial.medpath.com/news/19593746e2b9cbc1/hansoh-pharmaceutical-says-nmpa-granted-drug-registration-approval-of-third-indication 2025-03-10T19:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/f50040bb29d41b22/fda-clears-blackfinbio-s-gene-therapy-trial-for-rare-hereditary-spastic-paraplegia 2025-03-10T19:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/88676fd131966392/novel-drug-combination-shows-promise-against-kras-mutated-lung-cancer-resistance 2025-03-10T19:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/d3346d9cf8864dd4/mcmaster-university-launches-phase-2-trial-of-novel-inhaled-covid-19-vaccine 2025-03-10T19:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/9f607d951803502c/ema-urges-sponsors-to-maintain-accurate-ctis-data-for-enhanced-clinical-trial-visibility 2025-03-10T19:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/32777922324a0b4f/fda-expands-bear-implant-approval-for-acl-tears-in-children-and-partial-tears 2025-03-10T17:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/6c09d0590dc6504c/agilent-s-pd-l1-ihc-28-8-pharmdx-receives-eu-certification-for-lung-cancer-and-melanoma-diagnostics 2025-03-10T17:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/3f21841f8f02e292/eradivir-launches-phase-2-human-challenge-study-for-novel-influenza-therapeutic-ev25 2025-03-10T16:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/017b714cefd488a1/lixte-s-cancer-drug-lb-100-metabolism-pathway-discovered-opening-new-biomarker-strategy 2025-03-10T16:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/216a4831372ddcf2/alterome-therapeutics-initiates-phase-1-trial-of-novel-pan-kras-inhibitor-alta3263-for-advanced-solid-tumors 2025-03-10T16:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/e32880b6e427b91c/eu-approves-wainzua-eplontersen-for-hereditary-transthyretin-mediated-amyloidosis-with-polyneuropathy 2025-03-10T16:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/9157bd7b852ccc6c/cingulate-advances-ctx-1301-for-adhd-treatment-with-positive-phase-iii-safety-data-and-upcoming-fda-pre-nda-meeting 2025-03-10T16:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/04bc94bb722a3d5b/sunshine-biopharma-expands-portfolio-with-two-gastrointestinal-drugs-for-chronic-idiopathic-constipation 2025-03-10T16:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/0f3a653cd954a49c/eli-lilly-to-launch-mounjaro-in-major-emerging-markets-by-2025-as-global-demand-soars 2025-03-10T16:06:16+00:00 hourly 0.9 https://trial.medpath.com/news/91e1427cd345cc92/bristol-myers-squibb-acquires-2seventy-bio-for-102-million-as-gene-therapy-sector-faces-valuation-challenges 2025-03-10T16:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/3319630612683211/fda-grants-fast-track-designation-to-artiva-s-allonk-cell-therapy-for-autoimmune-diseases 2025-03-10T16:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/e91d0f9845b07516/natera-launches-heroes-trial-to-explore-treatment-de-escalation-in-her2-metastatic-breast-cancer 2025-03-10T16:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/b57b9e77c62e7383/fda-grants-ide-approval-for-lungpacer-s-aeronova-system-in-stari-phase-2-trial-for-respiratory-failure 2025-03-10T16:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/ecef5d1453e99e06/aligos-therapeutics-reports-recent-business-progress-and-fourth-quarter-and-full-year-2024-financial-results 2025-03-10T14:02:08+00:00 hourly 0.9 https://trial.medpath.com/news/7d77535d136b4299/arrowhead-s-aro-c3-shows-promising-results-in-iga-nephropathy-trial-with-89-reduction-in-c3-levels 2025-03-10T13:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/2c2482d5edbc0fae/immunome-initiates-phase-1-trial-of-ror1-targeted-adc-for-b-cell-lymphomas-and-solid-tumors 2025-03-10T13:34:58+00:00 hourly 0.9 https://trial.medpath.com/news/2ec35234ae66501d/agomab-s-agmb-129-shows-promising-results-in-phase-2a-trial-for-fibrostenosing-crohn-s-disease 2025-03-10T13:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/2de7974c9e7a6a53/beckman-coulter-s-dxc-500i-clinical-analyzer-receives-fda-clearance-enhancing-integrated-laboratory-testing-capabilities 2025-03-10T13:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/61590407e7581b63/vivus-launches-qsymia-in-uae-marking-first-middle-east-market-for-obesity-treatment 2025-03-10T13:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/581c1d35de6de6f9/glenmark-therapeutics-enters-otc-constipation-market-with-polyethylene-glycol-3350-launch 2025-03-10T13:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/07a9b5651976b48e/lupin-launches-first-generic-xarelto-in-us-market-despite-ongoing-patent-litigation 2025-03-10T13:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/c36c8764fbb395d3/beam-therapeutics-reports-breakthrough-in-alpha-1-antitrypsin-deficiency-treatment-with-beam-302-base-editing-therapy 2025-03-10T11:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/7bde6d9906b2c637/biovica-expands-oncology-partnership-with-us-biotech-firm-in-sek-2-5m-tka-testing-deal 2025-03-10T10:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/67e6375c7e8e8d6d/aavantgarde-to-present-promising-gene-therapy-data-for-usher-1b-and-stargardt-disease-at-arvo-2025 2025-03-10T10:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/e71af1b1ec3d3f6e/isotopia-launches-isoprotrace-for-prostate-cancer-imaging-in-germany-through-dsd-pharma-partnership 2025-03-10T10:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/18d0f00cf4747501/her2dx-r-genomic-assay-transforms-treatment-decisions-in-early-stage-her2-breast-cancer 2025-03-10T10:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/978e63fac59c1241/diamyd-medical-secures-additional-funding-for-phase-iii-type-1-diabetes-trial-with-fast-track-designation 2025-03-10T10:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/87799a303d2d7e4c/avacta-therapeutics-sells-launch-diagnostics-for-ps12-9m-to-focus-on-cancer-drug-development 2025-03-10T10:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/526729b63611ebfc/valo-therapeutics-secures-eur19m-funding-to-advance-novel-cancer-immunotherapy-platform 2025-03-10T10:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/05cf8aa60a671dc4/hikma-pharmaceuticals-prepares-to-launch-generic-versions-of-ozempic-and-wegovy 2025-03-10T08:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/cdda756213b2f4dd/onemednet-expands-access-to-regulatory-grade-imaging-data-through-strategic-partnerships 2025-03-10T08:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/9c0e2bdee62d9249/reshape-lifesciences-diabetes-neuromodulation-device-shows-promise-in-preclinical-studies 2025-03-10T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/ec43a384685a29db/tethis-and-sheba-medical-center-partner-on-ai-powered-liquid-biopsy-for-early-rectal-cancer-detection 2025-03-10T07:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/1c8fc066f000b0c4/sun-pharma-to-acquire-checkpoint-therapeutics-in-355-million-deal-for-novel-skin-cancer-treatment 2025-03-10T07:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/e0b655db9656952b/zydus-lifesciences-secures-usfda-approval-for-generic-ketoconazole-shampoo 2025-03-10T07:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/3c639247552029da/fda-reassesses-keytruda-and-opdivo-labels-based-on-pd-l1-biomarker-data-in-gastric-and-esophageal-cancers 2025-03-10T07:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/35dbe5dd2540cd3a/doer-biologics-completes-phase-2-enrollment-for-novel-tri-specific-agonist-targeting-severe-hypertriglyceridemia 2025-03-10T07:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/81104f403fb85f29/baird-medical-expands-global-footprint-secures-indonesian-approval-for-microwave-ablation-technology 2025-03-10T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/34615cac137c95bd/indian-pharma-companies-to-launch-generic-empagliflozin-at-90-lower-cost 2025-03-10T04:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/7ad450658aeacb7c/clearmind-medicine-s-psychedelic-combination-treatment-for-cocaine-addiction-receives-patent-publication-in-south-korea 2025-03-10T04:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/c6715591b94cfc3c/first-patient-dosed-in-groundbreaking-circular-rna-trial-for-radiation-induced-dry-mouth 2025-03-10T04:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/4f4c23ad4bbf64b6/galway-medtech-symphysis-medical-prepares-for-us-launch-of-innovative-cancer-palliative-care-device 2025-03-10T01:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/a57c3c72e7377696/sprim-global-investments-and-oneim-form-300m-joint-venture-to-accelerate-clinical-trial-financing 2025-03-09T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/3b8197602f05b345/ionis-advances-antisense-therapy-for-angelman-syndrome-to-phase-3-following-promising-clinical-results 2025-03-09T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/217a2e24e4d1819f/ctdna-testing-shows-promise-as-early-predictor-of-biliary-tract-cancer-recurrence 2025-03-09T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/826a6a421fb65956/innocare-pharma-s-tyk2-inhibitor-icp-488-shows-promising-phase-ii-results-for-psoriasis-treatment 2025-03-09T17:01:47+00:00 hourly 0.9 https://trial.medpath.com/news/841afb86ff5661ed/tyk-medicines-ty-9591-shows-superior-efficacy-over-osimertinib-in-treating-brain-metastases-from-egfr-mutated-lung-cancer 2025-03-09T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/5ceed873dc2afa4b/usfda-issues-warning-to-granules-india-over-critical-manufacturing-violations-at-telangana-facility 2025-03-09T14:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/30e325146c20538f/integrase-inhibitor-hiv-regimens-linked-to-higher-cardiometabolic-risks-reprieve-study-reveals 2025-03-09T14:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/0b028174fbed0ea3/fda-issues-warning-letter-to-granules-india-for-gmp-violations-at-telangana-facility 2025-03-09T13:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/d8813b3ea0d40646/viiv-healthcare-showcases-long-acting-hiv-innovations-and-pipeline-advances-at-croi-2025 2025-03-09T13:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/bcf4349f362bcfa5/va-hospital-clinical-trials-suspended-due-to-doge-cuts-creating-healthcare-crisis-for-veterans 2025-03-09T13:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/b7f68236e207ea2b/novel-drug-vip36-targets-cb1-receptor-for-pain-relief-without-cns-side-effects 2025-03-09T08:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/9fc2361543414b55/delgocitinib-cream-shows-super-response-in-nearly-half-of-chronic-hand-eczema-patients 2025-03-09T07:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/695b77e60a85ac04/same-day-administration-of-g-csf-after-chemotherapy-shows-promise-in-breast-cancer-treatment 2025-03-09T04:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/4ccff00a9e3a44cc/usc-norris-comprehensive-cancer-center-showcases-expanding-role-of-oncology-pharmacists-in-patient-care-and-research 2025-03-09T03:01:46+00:00 hourly 0.9 https://trial.medpath.com/news/7d49a7a72d731036/ruxolitinib-cream-shows-long-term-safety-and-efficacy-in-atopic-dermatitis-management 2025-03-09T02:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/51b452aa5ae57552/amaran-biotech-partners-with-nippon-fine-chemical-to-advance-nanoparticle-based-drug-manufacturing 2025-03-09T01:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/dec09f674846f794/sfa-therapeutics-reports-positive-phase-1b-results-for-oral-psoriasis-treatment-sfa-002 2025-03-09T01:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/866f04027b13065f/gilead-sciences-resolves-major-patent-disputes-with-1-25b-settlement-to-viiv-and-agreement-with-us-government 2025-03-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/80d55f086ee6800d/biotech-deal-landscape-february-march-2025-sees-surge-in-partnerships-across-multiple-therapeutic-areas 2025-03-08T23:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/6a6331771d5698a1/baricitinib-shows-promising-hair-regrowth-results-in-adolescents-with-severe-alopecia-areata-in-phase-3-trial 2025-03-08T20:02:30+00:00 hourly 0.9 https://trial.medpath.com/news/a5b110afbc0133be/rezivertinib-shows-superior-efficacy-over-gefitinib-in-egfr-mutated-nsclc-phase-iii-trial 2025-03-08T19:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/e7268ef32aa1f0d7/innovo-research-and-eagle-physicians-form-strategic-partnership-to-enhance-clinical-trial-access-in-value-based-care-settings 2025-03-08T19:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/c6fee64ff04d135d/dexcom-receives-fda-warning-letter-for-manufacturing-deficiencies-maintains-2025-outlook 2025-03-08T17:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/98799114814c0983/ftc-challenges-627m-gtcr-acquisition-of-surmodics-over-market-concentration-concerns 2025-03-08T17:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/8c7bdec1c0a8aa1c/ruxolitinib-cream-shows-promising-results-in-first-phase-3-trials-for-prurigo-nodularis 2025-03-08T16:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/92011af5322de2b2/japanese-intergroup-phase-iii-trial-evaluates-ramucirumab-plus-irinotecan-for-third-line-advanced-gastric-cancer-treatment 2025-03-08T13:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/db24a52fc0862d67/androgenetic-alopecia-pipeline-shows-promise-with-over-100-therapies-in-development 2025-03-08T13:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/02504b2a0881a98c/rocatinlimab-shows-promising-results-in-phase-3-trial-for-moderate-to-severe-atopic-dermatitis 2025-03-08T13:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/4deed68d5fc27042/immunogenesis-initiates-phase-i-ii-trial-of-imgs-101-combination-therapy-for-advanced-solid-tumors 2025-03-08T13:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/8271d356712ed93c/personalized-treatment-approaches-show-promise-in-t-cell-lymphoma-therapy 2025-03-08T10:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/433c938e1b29d86a/amgen-challenges-bristol-myers-squibb-patents-for-opdivo-yervoy-combination-therapy-in-patent-review-proceedings 2025-03-08T07:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/d64b47bbe751ec47/novel-radiotherapeutic-rhenium-obisbemeda-doubles-survival-time-in-glioblastoma-patients 2025-03-08T07:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/d577bbee9d48f5e1/senate-confirms-dr-marty-makary-as-fda-commissioner-signaling-potential-agency-reforms 2025-03-08T02:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/4478daa9c3733f7d/full-circles-therapeutics-secures-uspto-patent-for-revolutionary-circular-single-stranded-dna-genome-editing-platform 2025-03-08T01:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/6f1afae6ebc4eadf/bimiralisib-gel-shows-promising-results-in-phase-2-trial-for-actinic-keratosis 2025-03-08T01:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/60a72449a2cb4f61/bimzelx-shows-remarkable-five-year-efficacy-in-moderate-to-severe-plaque-psoriasis 2025-03-08T01:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/0b27c0183157c565/argenx-showcases-long-term-efficacy-and-safety-data-for-vyvgart-at-aan-2025-meeting 2025-03-08T01:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/c0996c278f324cab/fda-grants-dual-designations-to-neu-001-for-hirschsprung-disease-offering-hope-for-non-surgical-treatment 2025-03-08T01:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/c6c764a41b19f90c/fda-clears-ind-for-mrank-106-first-in-class-dual-wee1-yes1-kinase-inhibitor-for-advanced-solid-tumors 2025-03-08T01:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/21446a66634cfe05/real-world-vosoritide-treatment-shows-sustained-growth-benefits-in-children-with-achondroplasia 2025-03-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/28f002a901b54b49/unified-clinical-trial-systems-could-reduce-process-steps-by-60-industry-survey-reveals 2025-03-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dcf086986a5ae601/medicus-pharma-raises-11-2-million-to-advance-novel-microneedle-patch-for-basal-cell-carcinoma-treatment 2025-03-07T22:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/c4e3663d07fcf7b7/orphalan-makes-history-as-first-european-company-to-enter-china-s-wilson-disease-market-with-ke-pei-ou 2025-03-07T20:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/732f4eabc2b113a5/enveda-secures-150m-series-c-with-sanofi-backing-to-advance-ai-driven-natural-drug-discovery 2025-03-07T19:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/86322824119fddca/mission-barns-secures-fda-approval-for-cultivated-pork-fat-prepares-for-historic-us-market-launch 2025-03-07T19:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/7ca084c6ebe4b78f/fda-priority-review-vouchers-face-transparency-challenges-amid-rising-prices 2025-03-07T19:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/0133188be51496d4/phase-1-trial-shows-rhenium-186re-obisbemeda-doubles-survival-in-recurrent-glioblastoma-patients 2025-03-07T19:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/830040e67149872e/askbio-advances-phase-1-2-gene-therapy-trial-for-rare-muscular-dystrophy-with-second-cohort-dosing 2025-03-07T19:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/dad8dac89f92c734/nimbus-therapeutics-names-abbas-kazimi-as-new-ceo-in-planned-leadership-transition 2025-03-07T17:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/d45a1cb5784928e7/pharmacy-led-prior-authorization-model-dramatically-reduces-cancer-treatment-delays 2025-03-07T17:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/574e740eab1c7ca3/j-j-discontinues-depression-trials-for-aticaprant-after-insufficient-efficacy-results 2025-03-07T16:35:14+00:00 hourly 0.9 https://trial.medpath.com/news/83e0f9f0a38242d6/fda-clears-zimmer-biomet-s-metal-sensitive-revision-knee-implant-for-patients-with-allergies 2025-03-07T16:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/e8b40bef86780043/portland-digital-health-startup-secures-fda-approval-for-novel-parkinson-s-disease-device 2025-03-07T16:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/83c84b5ebdba7481/lupin-launches-generic-rivaroxaban-in-us-market-following-fda-approval 2025-03-07T16:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/45ec2d23f8b2207f/federal-circuit-upholds-regeneron-s-preliminary-injunction-against-samsung-bioepis-in-eylea-patent-dispute 2025-03-07T16:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/acac2870fc71fd3b/merck-s-enpatoran-shows-promise-for-lupus-rash-in-phase-2-trial-despite-mixed-results 2025-03-07T16:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/9f337323066b1a7a/sensorion-completes-patient-enrollment-in-phase-2a-trial-of-sens-401-for-cisplatin-induced-hearing-loss-prevention 2025-03-07T16:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/3ecd2045c8a23a03/alberta-expands-public-access-to-pluvicto-radioligand-therapy-for-advanced-prostate-cancer 2025-03-07T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8a778a3b026f1559/roche-launches-innovation-center-at-harvard-s-enterprise-research-campus-to-advance-cvrm-research-and-ai-applications 2025-03-07T14:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/408d31ca5fbaff8c/evotec-receives-20-million-from-bristol-myers-squibb-for-neurodegenerative-disease-program-advancement 2025-03-07T13:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/bdeaa1ba345678a3/pharmaceutical-industry-braces-for-236-billion-patent-cliff-by-2030-strategic-responses-from-major-players 2025-03-07T13:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/ef185e77a7e27a4a/novel-therapies-transform-rheumatology-landscape-in-early-2025 2025-03-07T10:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/367db89b7984568c/glp-1-agonists-show-significant-benefits-for-kidney-transplant-recipients-with-type-2-diabetes 2025-03-07T09:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/5250f5033b0f2b80/merck-kgaa-s-lupus-drug-fails-to-meet-primary-endpoint-in-phase-ii-sle-trial 2025-03-07T07:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/7ec4b131338ab012/fda-faces-turmoil-leadership-changes-and-operational-disruptions-raise-industry-concerns 2025-03-07T07:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/fae605e7cdeaf770/fda-clears-qiagen-s-qiastat-dx-gastrointestinal-panel-2-mini-b-for-clinical-use 2025-03-07T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/92e73f689542163c/over-120-pipeline-therapies-target-acute-myeloid-leukemia-as-research-intensifies 2025-03-07T03:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/4c8866f73bcfd239/healthcare-futurist-culture-of-happiness-and-ai-integration-critical-for-future-medical-success 2025-03-07T02:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/c41345be9c761b5c/croi-2025-to-showcase-breakthrough-research-in-hiv-covid-19-and-viral-infections 2025-03-07T02:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/e056b028dbe05002/puma-biotechnology-advances-clinical-development-of-alisertib-in-lung-and-breast-cancer 2025-03-07T02:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/20eb863bfa055099/managing-orphan-drug-supply-chains-strategies-to-minimize-stock-losses-in-european-markets 2025-03-07T02:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/eff70e0ea009a45d/federal-circuit-affirms-dismissal-of-patent-applicant-s-delayed-appointments-clause-challenge 2025-03-07T02:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/9d41e6633611b599/cidara-completes-5000-patient-enrollment-in-phase-2b-universal-flu-prevention-trial-secures-105m-financing 2025-03-07T01:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/ad73d7c624a24ba8/probiogen-and-marea-achieve-key-manufacturing-milestone-for-novel-acromegaly-antibody-treatment 2025-03-07T01:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/47910ae2a5166fa9/gbm-health-secures-1-5m-grant-to-advance-ai-diagnostics-and-sustainable-biomanufacturing 2025-03-07T01:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/258de39f04433a19/novel-chemo-immunotherapy-approach-shows-promise-for-advanced-hpv-negative-head-and-neck-cancer 2025-03-07T01:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/388233ebb489f53d/fda-grants-compassionate-use-approval-for-novel-reverse-hip-replacement-system-in-spinal-fusion-patient 2025-03-07T01:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/99ad3f6b0dac4d84/novo-nordisk-plans-india-entry-for-ozempic-despite-looming-patent-expiry-as-indian-pharma-giants-prepare-generic-alternatives 2025-03-07T00:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/01169e2d5a7f5035/axplora-expands-adc-manufacturing-capabilities-with-new-payload-facility-in-france 2025-03-07T00:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/f7790fad40ed293b/fda-approves-dermasensor-first-ai-powered-skin-cancer-detection-device-for-primary-care 2025-03-06T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/d0f4bfecd8821f76/novel-3d-bioprinter-developed-to-accelerate-drug-discovery-with-enhanced-human-like-tissue-models 2025-03-06T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fc23526e06060815/digital-twins-transform-rare-disease-drug-development-with-virtual-trials-and-ai-powered-simulations 2025-03-06T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/c3a61db8ba6c1252/alnylam-s-vutrisiran-shows-strong-efficacy-in-attr-cardiomyopathy-setting-stage-for-new-treatment-standard 2025-03-06T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/61499cdc8658591b/partner-treatment-halves-bacterial-vaginosis-recurrence-rate-in-landmark-trial 2025-03-06T23:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/abe4549f555e002b/first-patients-enrolled-in-novel-gene-therapy-trial-for-high-grade-glioma 2025-03-06T22:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/1fbb38983b7de5ec/cdsco-panel-mandates-phase-iii-trial-of-baloxavir-marboxil-in-indian-population 2025-03-06T22:35:13+00:00 hourly 0.9 https://trial.medpath.com/news/787b736779bec0af/tenaya-therapeutics-raises-52-5-million-in-strategic-units-offering-to-advance-cardiac-gene-therapy-pipeline 2025-03-06T22:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/32c1733954eaa3c8/modern-sports-medicine-wellness-partners-with-neuralcure-ai-to-transform-orthobiologic-treatment-using-ai-powered-diagnostics 2025-03-06T22:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/06a13cc8a3332b62/nice-to-reassess-ps60000-alzheimer-s-drugs-lecanemab-and-donanemab-after-initial-rejection 2025-03-06T22:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/98fdc004c16b94b7/stryker-unveils-artix-thrombectomy-system-a-breakthrough-in-arterial-blood-clot-treatment 2025-03-06T22:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/f9fd4fb5f8c5c16a/astellas-and-yaskawa-electric-form-30m-joint-venture-to-revolutionize-cell-therapy-manufacturing 2025-03-06T22:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/65abc4d017f93038/fda-expands-furoscix-approval-to-include-edema-treatment-in-ckd-patients 2025-03-06T22:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/a9a80395ccf52698/spatial-analysis-reveals-key-microglial-mechanisms-in-amyloid-b-clearance-following-alzheimer-s-immunotherapy 2025-03-06T22:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/ae5f02850c722723/oculis-advances-novel-therapies-for-ophthalmic-diseases-with-promising-pipeline-development 2025-03-06T22:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/5db6d6a2c569a03c/mindmed-reports-strong-financial-position-with-273-7m-cash-reserve-extending-operations-through-2027 2025-03-06T21:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/5e1cfaeb6599bda1/voquezna-achieves-55-3m-revenue-in-first-full-year-shows-strong-market-growth-with-300000-prescriptions 2025-03-06T21:02:22+00:00 hourly 0.9 https://trial.medpath.com/news/c4b944df4a541452/enveric-biosciences-to-divest-psyai-trademark-focuses-on-novel-neuroplastogen-development 2025-03-06T20:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/67c31daf548ac393/nice-rejects-nhs-coverage-of-eli-lilly-and-biogen-s-alzheimer-s-drugs-due-to-cost-concerns 2025-03-06T20:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/331f1c786102d561/european-patent-board-revokes-c1-esterase-inhibitor-patent-for-kidney-transplant-rejection-treatment 2025-03-06T19:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/e91f0b952291ebf4/astrazeneca-india-secures-regulatory-approval-for-novel-hyperkalaemia-treatment-lokelma 2025-03-06T19:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/71071e2222e38235/dupilumab-shows-strong-efficacy-in-chronic-spontaneous-urticaria-across-all-bmi-ranges 2025-03-06T19:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/0fe98903857fb31f/fda-clinical-trial-launches-for-revolutionary-3d-printed-airway-device-to-treat-infant-breathing-disorder 2025-03-06T19:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/0df8f8f77c93cd67/remibrutinib-shows-promising-long-term-efficacy-in-phase-3-trials-for-chronic-spontaneous-urticaria 2025-03-06T19:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/69d94e28f6cef186/beckley-psytech-achieves-full-patient-enrollment-in-phase-iib-trial-for-treatment-resistant-depression 2025-03-06T19:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/8eb24740537917bf/first-patients-receive-groundbreaking-autologous-stem-cell-treatment-for-parkinson-s-disease-in-phase-1-trial 2025-03-06T19:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/311cdaf02452f1fa/mindmed-reports-strong-financial-position-and-progress-in-anxiety-treatment-development 2025-03-06T19:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/0078231f1e83d5a4/plus-therapeutics-receives-fda-orphan-drug-designation-for-novel-lung-cancer-metastasis-treatment 2025-03-06T17:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/0197aff62ee586e0/tonix-s-fibromyalgia-treatment-shows-promising-phase-3-results-fda-decision-expected-in-2025 2025-03-06T17:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/4fd7fa3a9754122b/amgen-launches-phase-3-trials-for-monthly-obesity-drug-maritide 2025-03-06T17:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/de6f66c803d5f37c/maryland-senate-weighs-200m-medicaid-coverage-for-glp-1-weight-loss-drugs 2025-03-06T17:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/a5ced09b678a43f0/eth-zurich-unveils-revolutionary-ai-algorithm-for-structure-based-drug-discovery 2025-03-06T17:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/d650498df33418ac/oragenics-advances-onp-002-to-phase-ii-trial-for-concussion-treatment 2025-03-06T16:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/32f3343a3d27efe3/polish-research-team-secures-eur1-2m-grant-for-novel-alzheimer-s-adc-drug-development 2025-03-06T16:36:28+00:00 hourly 0.9 https://trial.medpath.com/news/2024cb5f8cd7b35c/phantom-neuro-s-neural-interface-platform-receives-dual-fda-fast-track-designations-for-prosthetic-control 2025-03-06T16:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/541b4b79c08e3abc/biocon-biologics-and-civica-partner-to-increase-affordable-insulin-aspart-access-in-us-market 2025-03-06T16:35:52+00:00 hourly 0.9 https://trial.medpath.com/news/8f9408be235c5995/novel-mrna-vaccine-shows-promise-in-phase-3-trials-for-cytomegalovirus-prevention 2025-03-06T16:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/0eedc36112678581/izafe-group-s-dosell-digital-medication-dispenser-expands-across-european-markets-with-9-growth 2025-03-06T16:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/3f1ca588935c2b6d/symbiosis-pharmaceutical-services-achieves-zero-gmp-observations-in-fda-gene-therapy-inspection 2025-03-06T16:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/9a9b36dfeaf9c037/scienture-launches-rezenopy-most-potent-naloxone-nasal-spray-for-opioid-overdose-treatment 2025-03-06T16:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/7185122d0970e7d7/fda-grants-orphan-drug-designation-to-rhenium-obisbemeda-for-lung-cancer-leptomeningeal-metastases 2025-03-06T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/397b6643fc14faad/adimune-advances-adi-100-towards-clinical-trials-for-multiple-autoimmune-diseases 2025-03-06T16:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/2e1fadea44c2d9f7/novo-nordisk-explores-glp-1-drugs-potential-in-addiction-treatment 2025-03-06T16:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/2c4e95bde45c7851/icosabutate-shows-promising-anti-fibrotic-results-in-phase-2b-mash-trial 2025-03-06T16:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/2038e589791d5999/fda-s-project-frontrunner-reshapes-early-phase-oncology-drug-development-strategy 2025-03-06T16:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/0d6d234ecf144e95/lindus-health-and-tiefenbacher-group-launch-virtual-clinical-trial-for-me-cfs-treatment 2025-03-06T16:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/3e964cc717753326/neurocrine-launches-phase-1-trial-of-novel-vmat2-inhibitor-for-neurological-disorders 2025-03-06T14:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/ae7dc2594bc62be7/alx-oncology-launches-phase-ii-studies-in-breast-and-colorectal-cancer-receives-jefferies-upgrade 2025-03-06T14:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/18b26f8e7e7ef1fe/itm-s-phase-3-radiopharmaceutical-shows-promise-in-neuroendocrine-tumor-treatment 2025-03-06T14:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/c61710a99d941d2b/persica-s-novel-antibiotic-shows-promise-in-lower-back-pain-phase-ib-trial 2025-03-06T14:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/b5cd7b0f24109b7c/taiwan-court-ruling-tightens-standards-for-pharmaceutical-patent-term-extensions 2025-03-06T14:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/798e57459cd98782/hutchmed-completes-enrollment-for-phase-ii-registration-trial-of-fanregratinib-in-fgfr2-fusion-cholangiocarcinoma 2025-03-06T13:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/629a2c7add668b4a/fda-grants-breakthrough-therapy-designation-to-olverembatinib-for-ph-leukemia-treatment 2025-03-06T13:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/bdcc97f4985a4327/aion-labs-and-biomed-x-launch-ai-initiative-to-revolutionize-multi-target-drug-discovery 2025-03-06T13:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/1d4e058ce86e3a06/congress-s-failure-to-renew-priority-review-voucher-program-threatens-rare-disease-drug-development 2025-03-06T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/a2a26e262a6d33c1/isomorphic-labs-secures-600m-to-advance-ai-powered-drug-discovery-platform 2025-03-06T11:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/aac0be59a940a6eb/eli-lilly-expands-zepbound-access-through-noom-and-teladoc-partnerships 2025-03-06T11:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/33dc8a3dc1159d3c/vaxart-s-oral-norovirus-vaccine-shows-promising-immune-response-in-elderly-phase-1b-trial 2025-03-06T10:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/c13beece0dfd4ed7/ten-adalimumab-biosimilars-now-available-in-us-market-following-latest-fda-approval 2025-03-06T10:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/9245b22b7123e7a7/trestle-bio-and-humacyte-partner-to-develop-bioengineered-kidney-tissues-with-vascular-perfusion 2025-03-06T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/028f90320a0a2d35/tivic-health-advances-personalized-non-invasive-vagus-nerve-stimulation-technology-with-promising-new-data 2025-03-06T07:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/ade1a21a772d2692/act-genomics-partners-with-mprobe-to-launch-integrated-proteogenomics-platform-for-advanced-cancer-care-in-asia 2025-03-06T07:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/10d83d398132e993/cerus-secures-ce-mark-for-next-gen-intercept-blood-pathogen-inactivation-system 2025-03-06T07:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/53f1d9d6f908a588/fda-rejects-vanda-s-hetlioz-application-for-insomnia-treatment-due-to-insufficient-trial-data 2025-03-06T07:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/29811ebbe71b5083/cstone-advances-cs5001-ror1-adc-to-phase-ib-trial-for-first-line-dlbcl-treatment 2025-03-06T07:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/5495d5bb0b55ef37/lifeward-partners-with-corlife-to-expand-workers-compensation-access-to-rewalk-exoskeleton 2025-03-06T07:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/6b2b0ea7452d9934/icon-partners-with-mural-health-to-enhance-clinical-trial-patient-experience 2025-03-06T07:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/c458e985f7549fe0/hanall-s-batoclimab-receives-orphan-drug-designation-in-japan-for-thyroid-eye-disease 2025-03-06T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f72bb69797c0bdb1/dermata-completes-patient-visits-in-pivotal-phase-3-xyngari-trial-for-moderate-to-severe-acne 2025-03-06T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/cee44dd5b85da272/biosimilars-market-shows-mixed-progress-36b-in-savings-despite-adoption-challenges 2025-03-06T04:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/e2e724b9b75507f9/everest-medicines-initiates-first-in-human-trial-of-personalized-mrna-cancer-vaccine-evm16 2025-03-06T03:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/c0f3858eadff187f/comparative-oncology-breakthrough-how-pet-dogs-are-advancing-human-cancer-treatment 2025-03-06T03:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/1ba52fbec4617722/asco-issues-major-updates-to-pleural-mesothelioma-treatment-guidelines-emphasizing-immunotherapy-and-selective-surgery 2025-03-06T03:02:45+00:00 hourly 0.9 https://trial.medpath.com/news/1cd3f4fa880ab284/itf-therapeutics-establishes-new-u-s-hub-for-rare-disease-innovation-in-massachusetts 2025-03-06T03:02:24+00:00 hourly 0.9 https://trial.medpath.com/news/bae0b25e2bb3408c/survey-reveals-critical-gaps-in-chronic-hand-eczema-understanding-and-treatment-options 2025-03-06T03:02:04+00:00 hourly 0.9 https://trial.medpath.com/news/19df15539c65e4c6/nih-director-nominee-bhattacharya-faces-senate-scrutiny-over-research-funding-and-covid-19-stance 2025-03-06T02:34:56+00:00 hourly 0.9 https://trial.medpath.com/news/7c4088110473b947/sandoz-reports-9-growth-in-2024-driven-by-strong-biosimilar-performance 2025-03-06T02:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/f0664d788a1846e0/expanding-glp-1-access-a-collaborative-framework-to-address-cost-and-accessibility-challenges 2025-03-06T02:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/560329d4b08c5c45/healthcare-llms-face-critical-equity-challenges-new-guidelines-address-bias-and-access-concerns 2025-03-06T02:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/87f8adfc4bcfeff1/delphia-pioneers-activation-lethality-platform-for-novel-cancer-treatment-approach 2025-03-06T02:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/e41742a875a34f53/nyxoah-to-present-innovative-osa-treatment-at-oppenheimer-healthcare-conference 2025-03-06T02:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/6a36af6ed784609c/olverembatinib-receives-third-breakthrough-therapy-designation-in-china-for-ph-all-treatment 2025-03-06T01:18:05+00:00 hourly 0.9 https://trial.medpath.com/news/bb6fd84c42e837b9/novo-holdings-and-ta-associates-form-strategic-partnership-to-accelerate-biocomposites-growth-in-infection-management 2025-03-06T01:17:46+00:00 hourly 0.9 https://trial.medpath.com/news/10e8ade2e49ea398/quantoom-biosciences-and-techinvention-partner-to-advance-rna-vaccine-production-in-india 2025-03-06T01:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/12c17b70d3ff83a6/fda-approves-enhanced-perceval-plus-surgical-valve-with-lancelot-technology 2025-03-06T01:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/a99abcced46e0970/orphan-drug-market-growth-slowing-but-remains-strategic-priority-for-pharma 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/00aa0c6a62beac52/fda-approves-cabenuva-first-long-acting-injectable-hiv-treatment-replaces-daily-pills 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f71d8e31be6338bd/the-evolution-of-clinical-trials-embracing-technology-and-collaboration-in-a-post-pandemic-world 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3429b09c04663643/bi-764532-t-cell-engager-shows-promise-in-dll3-positive-neuroendocrine-carcinomas-with-29-response-rate 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4414f9c47000f0f3/beckman-coulter-and-rarity-bioscience-partner-to-revolutionize-oncology-research-with-enhanced-flow-cytometry 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/18b27159c12deecd/ai-supported-mammography-screening-demonstrates-17-6-increase-in-breast-cancer-detection-in-real-world-study 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f3fa0994c4df64a4/tenax-therapeutics-secures-25m-private-placement-to-advance-phase-3-cardiopulmonary-trials 2025-03-05T23:44:45+00:00 hourly 0.9 https://trial.medpath.com/news/de0e457f1d579c76/study-reveals-surprising-link-between-patent-prosecution-length-and-invalidity-risk 2025-03-05T23:44:28+00:00 hourly 0.9 https://trial.medpath.com/news/a8c127e5fdbe8fe0/car-t-cell-therapy-achieves-long-term-remission-in-autoimmune-diseases-through-complete-b-cell-depletion 2025-03-05T23:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/001ffb876315bd34/global-ebola-pipeline-expands-with-multiple-promising-therapies-in-development-through-2025 2025-03-05T23:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/b19bd98a23c9466b/brukinsa-rchop-combination-shows-promise-in-double-expressor-lymphoma-treatment-with-89-6-response-rate 2025-03-05T22:14:16+00:00 hourly 0.9 https://trial.medpath.com/news/90f3200ecd25d3e0/novel-combination-therapy-trial-launches-for-inflammatory-diseases-with-hudsonalpha-s-genomic-support 2025-03-05T22:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/4e71a04badb3d479/ataraxis-ai-secures-20-4m-series-a-to-launch-ai-powered-breast-cancer-diagnostic-platform 2025-03-05T22:13:34+00:00 hourly 0.9 https://trial.medpath.com/news/7ee6ab1221443be3/novel-peptide-brp-shows-promise-as-alternative-to-ozempic-for-weight-loss-with-fewer-side-effects 2025-03-05T22:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/54be6bfd90f71f23/study-reveals-significant-racial-disparities-in-diabetic-macular-edema-clinical-trials 2025-03-05T22:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/cb72f7d932b13b98/keytruda-s-cost-effectiveness-questioned-in-advanced-cervical-cancer-treatment-despite-clinical-benefits 2025-03-05T22:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/b3403ac62ed1942d/car-t-cell-therapy-pipeline-surges-with-180-companies-advancing-novel-cancer-treatments 2025-03-05T22:11:53+00:00 hourly 0.9 https://trial.medpath.com/news/c2bdfb104a99c4b9/robust-pipeline-for-nasopharyngeal-cancer-treatment-emerges-with-25-pharmaceutical-companies-developing-novel-therapies 2025-03-05T21:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/f58eae27343b5055/cps-technologies-secures-third-u-s-army-sbir-contract-to-develop-advanced-materials-for-military-vehicles 2025-03-05T21:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/846acef33639fb4e/kkr-and-ajax-health-launch-flowmod-to-develop-novel-heart-failure-treatment-platform 2025-03-05T20:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/b789ad966e512b5a/quebec-leads-canada-in-hiv-prevention-first-to-cover-long-acting-injectable-prep-apretude 2025-03-05T19:38:29+00:00 hourly 0.9 https://trial.medpath.com/news/f923b61e51904536/jazz-pharmaceuticals-acquires-chimerix-strengthening-late-stage-pipeline 2025-03-05T19:38:15+00:00 hourly 0.9 https://trial.medpath.com/news/cc98a3d741f0592e/gfap-biomarker-analysis-shows-ozanimod-s-impact-on-ms-disease-progression-in-enlighten-trial 2025-03-05T19:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/2997817779188ba6/amgen-launches-phase-iii-maritime-trials-for-novel-obesity-drug-maritide 2025-03-05T19:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/e0ab81c3eb781119/novel-small-molecule-drug-shows-promise-in-treating-inflammatory-bowel-disease 2025-03-05T19:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/f2273d258273d104/aspirin-shows-promise-in-preventing-cancer-metastasis-by-boosting-immune-response 2025-03-05T19:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/ab0b15aa14502200/biocon-pharma-secures-fda-approval-for-generic-cancer-and-blood-disorder-treatments 2025-03-05T19:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/5af16f760c2d6cef/novo-nordisk-launches-home-delivery-service-for-wegovy-at-499-monthly-for-cash-paying-patients 2025-03-05T17:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/b254635b72ce9f32/fda-places-biontech-s-malaria-vaccine-trial-on-clinical-hold 2025-03-05T17:38:03+00:00 hourly 0.9 https://trial.medpath.com/news/bb649313f11d9992/patent-dispute-emerges-between-merck-and-halozyme-over-injectable-keytruda-formulation 2025-03-05T17:37:43+00:00 hourly 0.9 https://trial.medpath.com/news/552c17df4ceee599/tscan-therapeutics-reports-promising-results-in-blood-cancer-trial-with-only-8-relapse-rate 2025-03-05T17:10:53+00:00 hourly 0.9 https://trial.medpath.com/news/2a4b9eedb8a39788/oppenheimer-initiates-coverage-of-abeona-s-pz-cel-for-rare-skin-disease-with-optimistic-outlook 2025-03-05T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/ded3c1dd46b4bb1f/calcimedica-secures-32-5m-credit-facility-to-advance-crac-channel-inhibitor-development 2025-03-05T17:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/391e119c1253ad10/fda-endorses-expanded-phase-3-program-for-tenax-s-novel-ph-hfpef-treatment-tnx-103 2025-03-05T17:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/5138b36354bd2100/phase-3-trial-shows-ivermectin-mass-drug-administration-falls-short-in-malaria-control-efforts 2025-03-05T17:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/9749d47e15dba738/novel-senolytic-drug-shows-promise-for-masld-and-liver-cancer-treatment 2025-03-05T16:36:28+00:00 hourly 0.9 https://trial.medpath.com/news/81daa602695b7cf1/fda-clears-ind-for-bioheng-s-off-the-shelf-car-t-therapy-ctd402-for-t-cell-leukemia-lymphoma 2025-03-05T16:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/ad6daf3bdae70a60/trimtech-therapeutics-secures-31m-seed-funding-for-novel-protein-degradation-platform-targeting-neurodegenerative-diseases 2025-03-05T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/4817bc95e004ad01/lam561-shows-promising-pfs-data-in-mgmt-methylated-glioblastoma-patients 2025-03-05T16:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/26ed854eb80d252b/amgen-charts-growth-strategy-amid-patent-cliff-biosimilars-and-therapeutic-innovation-take-center-stage 2025-03-05T16:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/7f567e1aa947b3c2/university-of-colorado-cancer-center-partners-with-flatiron-health-to-streamline-clinical-trial-data-management 2025-03-05T16:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/16e814f5d3da9eb6/lisata-and-gatc-health-partner-to-accelerate-drug-development-using-ai-platform 2025-03-05T16:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/c2a3fc8a94e78636/fda-places-clinical-hold-on-biontech-s-novel-malaria-vaccine-trial 2025-03-05T16:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/4f379083908a0b88/lipogems-completes-patient-enrollment-in-pivotal-fda-trial-for-knee-osteoarthritis-treatment 2025-03-05T16:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/d4641dea5c658abe/whims-trial-legacy-pioneering-study-reshapes-women-s-health-research-and-alzheimer-s-understanding 2025-03-05T16:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/ed9e6c3c2b2c77c2/asceneuron-discontinues-phase-i-alzheimer-s-trial-of-tau-targeting-drug-asn90 2025-03-05T16:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/0d21a2306370e467/pfizer-s-litfulo-becomes-first-nhs-approved-treatment-for-severe-alopecia-areata 2025-03-05T14:39:27+00:00 hourly 0.9 https://trial.medpath.com/news/13ae8878e51cbcb3/roche-s-tiragolumab-combination-shows-inferior-outcomes-in-advanced-nsclc-trial 2025-03-05T14:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/75e88633667525f1/osivax-raises-eur10m-in-series-b-funding-to-advance-broad-spectrum-influenza-vaccine-development 2025-03-05T13:39:35+00:00 hourly 0.9 https://trial.medpath.com/news/60f92e430ba99e14/jazz-pharmaceuticals-to-acquire-chimerix-for-935m-gaining-novel-brain-tumor-drug-candidate 2025-03-05T13:39:12+00:00 hourly 0.9 https://trial.medpath.com/news/dbf1114e8879af98/pliant-therapeutics-discontinues-phase-2b-trial-in-idiopathic-pulmonary-fibrosis 2025-03-05T13:38:57+00:00 hourly 0.9 https://trial.medpath.com/news/01be9618f3ac03c3/clinical-trial-validates-safety-shot-s-breakthrough-alcohol-reduction-supplement-in-peer-reviewed-study 2025-03-05T13:38:37+00:00 hourly 0.9 https://trial.medpath.com/news/ddb30af878b0c2f1/zydus-launches-anvimo-game-changing-cmv-prevention-drug-for-transplant-patients-at-91-lower-cost 2025-03-05T13:12:43+00:00 hourly 0.9 https://trial.medpath.com/news/343732f8de03ca84/australia-s-tga-denies-second-approval-attempt-for-eisai-s-alzheimer-s-drug-leqembi 2025-03-05T13:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/f92732ad00bc94d4/sanyoubio-launches-comprehensive-suite-of-73-bispecific-antibody-reference-products-to-accelerate-drug-development 2025-03-05T13:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/43d60a60eb502bb0/insilico-medicine-develops-novel-ai-designed-cdk12-13-inhibitors-for-treatment-resistant-cancers 2025-03-05T13:11:43+00:00 hourly 0.9 https://trial.medpath.com/news/6b59092211e5c015/enspire-dbs-therapy-expands-pivotal-stroke-recovery-trial-with-second-site-implementation 2025-03-05T13:11:19+00:00 hourly 0.9 https://trial.medpath.com/news/0b21d02982010d71/ai-revolutionizes-regenerative-medicine-drug-development-accelerating-parkinson-s-treatment-research 2025-03-05T13:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/0e3a768bf03137e4/groundbreaking-car-t-cell-and-transplantation-research-unveiled-at-2025-tandem-meeting 2025-03-05T13:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/9016c968e72c8bbf/understanding-prognostic-vs-predictive-biomarkers-key-distinctions-in-cancer-treatment-strategy 2025-03-05T13:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/a04c2b26789973f6/olverembatinib-shows-promise-in-heavily-pretreated-chronic-myeloid-leukemia 2025-03-05T13:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/1bf3c3a55ae997bc/apogee-s-novel-atopic-dermatitis-drug-apg777-shows-promising-safety-and-extended-half-life-in-phase-1-trial 2025-03-05T11:39:55+00:00 hourly 0.9 https://trial.medpath.com/news/66257cebe74cc184/olympus-introduces-advanced-retentia-hemoclip-for-enhanced-gi-tract-hemostasis-control 2025-03-05T11:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/f175b99fb0b39066/fda-approves-first-generic-rivaroxaban-2-5mg-for-cardiovascular-and-peripheral-artery-disease-prevention 2025-03-05T11:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/1e78b83de52a6f1d/federal-circuit-rules-against-teva-s-orange-book-patent-listings-for-proair-hfa-inhaler 2025-03-05T11:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/dfdf3be5eb7e312e/beigene-s-tislelizumab-secures-first-line-approval-for-advanced-nsclc-in-china 2025-03-05T11:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/d6866e34ba43bf6c/nih-funding-critical-for-advancing-cancer-research-and-treatment-innovation 2025-03-05T11:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/53a6d11724acb3dc/mass-general-brigham-reports-100-success-rate-in-corneal-stem-cell-therapy-trial 2025-03-05T11:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/6bee56e406747782/study-reveals-hr-mp-h2-breast-cancers-share-key-features-with-triple-negative-disease-opening-new-treatment-pathways 2025-03-05T11:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/117d24741e7343ea/chatgpt-shows-potential-in-developing-dietary-plans-for-masld-management-study-finds 2025-03-05T11:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/d23c038539772b6e/fda-clears-path-for-nebokitug-in-primary-sclerosing-cholangitis-treatment-following-successful-phase-2-meeting 2025-03-05T11:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/3cad06002da87ecb/health-canada-approves-spark-biomedical-s-drug-free-neurostimulation-device-for-opioid-withdrawal 2025-03-05T09:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/7c27b3e904ce2a0e/rigel-pharmaceuticals-reports-strong-growth-with-tavalisse-and-rezlidhia-in-2024-expands-global-reach 2025-03-05T08:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/3c5085be1ff0c447/fda-s-single-irb-mandate-set-to-streamline-clinical-trial-reviews-by-late-2024 2025-03-05T08:01:42+00:00 hourly 0.9 https://trial.medpath.com/news/1a3421f78d51cb97/sernova-biotherapeutics-secures-5-million-in-financing-to-advance-type-1-diabetes-functional-cure 2025-03-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/38543056d7c8e382/precise-hl-trial-launches-to-reduce-chemotherapy-in-hodgkin-lymphoma-using-ctdna-testing 2025-03-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0f3bb77ee66f057e/ivosidenib-plus-cpx-351-shows-promise-in-idh1-mutated-aml-and-high-risk-mds-trial 2025-03-05T07:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/71cf523c858c921e/fda-signals-potential-shift-in-biosimilar-development-requirements-moving-away-from-phase-iii-trials 2025-03-05T07:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/a2edeb31974c19c7/garuda-therapeutics-names-avanish-vellanki-as-new-ceo-to-advance-off-the-shelf-stem-cell-platform 2025-03-05T05:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/d2da4e68ebb41d66/tc-biopharm-to-acquire-ophthalmic-pharmaceutical-company-with-fda-approved-glaucoma-treatment 2025-03-05T05:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/68f3ba6150072eb6/celon-pharma-s-pde10a-inhibitor-shows-significant-promise-in-phase-2-trial-for-parkinson-s-disease-dyskinesia 2025-03-05T04:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/f0d20f51cd3de6ac/fda-clears-epredia-s-e1000-dx-digital-pathology-solution-for-cancer-diagnostics 2025-03-05T04:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/93e4da557b474481/matica-biotechnology-partners-with-childs-cure-to-develop-gene-therapy-for-rare-genetic-disorders 2025-03-05T04:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/d0266f663a25f6eb/wehi-and-moderna-launch-pioneering-mrna-partnership-to-combat-autoimmune-diseases 2025-03-05T04:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/4c8391ea227ca467/breakthrough-artificial-photosynthesis-system-converts-waste-into-pharmaceutical-compounds 2025-03-05T04:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/290c48c50331629b/eisai-and-sato-pharmaceutical-restructure-nailin-antifungal-marketing-partnership-in-japan 2025-03-05T04:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/958e571934088ec7/microbiome-therapeutics-pipeline-expands-with-180-novel-therapies-in-development-across-140-companies 2025-03-05T04:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/5e09910760fb3d5f/pharmamar-advances-lurbi-eadine-development-with-japanese-licensing-talks-and-european-submission-plans 2025-03-05T02:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/dbd2ccc04a81d4b5/fda-removes-cardiovascular-black-box-warning-from-testosterone-products-following-traverse-trial-results 2025-03-05T02:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/ec540d30e3dada53/cantargia-s-can10-shows-promising-phase-1-results-for-hidradenitis-suppurativa-treatment 2025-03-05T01:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/e501a9934ad7ce8c/antihistamine-addition-to-atezolizumab-doubles-survival-rates-in-metastatic-urothelial-cancer 2025-03-05T01:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/2ed8c9b3418e0812/oceanagold-advances-wharekirauponga-project-with-fast-track-application-and-high-grade-results 2025-03-05T01:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/493ca345dedfe50a/fda-updates-testosterone-product-labels-following-traverse-trial-safety-data 2025-03-05T01:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/86290f0439e8bcbe/boehringer-ingelheim-advances-dual-action-obesity-drug-survodutide-to-phase-3-trials 2025-03-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cfaf9c2e460312c5/fatal-immune-checkpoint-inhibitor-overlap-syndrome-new-case-series-reveals-critical-management-insights 2025-03-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0b495abd95c35805/minoryx-initiates-phase-2a-trial-of-leriglitazone-for-rett-syndrome 2025-03-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/86305ab5351e89fe/capricor-s-deramiocel-receives-fda-priority-review-for-duchenne-muscular-dystrophy-treatment 2025-03-04T22:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/1901f6239ba0daf6/novel-fecal-microbiota-pill-enters-clinical-trial-for-advanced-pancreatic-cancer-treatment 2025-03-04T22:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/6eb17af7a9f90ab1/nuvation-bio-secures-250m-financing-for-us-launch-of-ros1-inhibitor-taletrectinib 2025-03-04T22:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/4df0fd3ba9b10851/cumberland-pharmaceuticals-reports-breakthrough-in-dmd-treatment-and-11-6-q4-revenue-growth 2025-03-04T22:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/5488f25f46afee39/advanced-emollient-plus-formulation-shows-superior-efficacy-in-atopic-dermatitis-treatment 2025-03-04T22:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/4ec1e2809cc4500b/novel-pipeline-drugs-show-promise-in-treating-severe-hypertriglyceridemia 2025-03-04T20:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/82ba9ee52e83b26e/senores-pharmaceuticals-acquires-14-andas-from-dr-reddy-s-in-421m-market-opportunity-deal 2025-03-04T20:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/a4ebe8999bbf6907/mass-general-brigham-reports-universal-patient-response-in-corneal-stem-cell-therapy-trial 2025-03-04T20:00:09+00:00 hourly 0.9 https://trial.medpath.com/news/acb14bec4f3dc624/first-ascent-biomedical-secures-florida-grant-to-expand-ai-driven-cancer-treatment-platform 2025-03-04T19:59:28+00:00 hourly 0.9 https://trial.medpath.com/news/255d72cb78476983/ema-s-chmp-issues-new-drug-recommendations-and-marketing-authorization-updates 2025-03-04T19:59:11+00:00 hourly 0.9 https://trial.medpath.com/news/a2c1866dcabd7859/iqvia-revolutionizes-clinical-trial-workflows-with-launch-of-site-lab-navigator-e-requisition-platform 2025-03-04T19:58:52+00:00 hourly 0.9 https://trial.medpath.com/news/01192942b85732a8/cleveland-clinic-reports-first-successful-tumor-infiltrating-lymphocyte-therapy-in-metastatic-melanoma-patient 2025-03-04T19:58:29+00:00 hourly 0.9 https://trial.medpath.com/news/a2d3a4fbf3598e89/fda-and-nih-policy-shifts-spark-new-focus-on-clinical-trial-accessibility-and-technology-solutions 2025-03-04T19:58:13+00:00 hourly 0.9 https://trial.medpath.com/news/aae0a4d1c8c636e4/seagen-wins-42m-patent-verdict-against-daiichi-sankyo-over-enhertu-breast-cancer-drug 2025-03-04T19:56:34+00:00 hourly 0.9 https://trial.medpath.com/news/df0c359114162d34/medable-secures-cnil-approval-for-digital-clinical-trial-solutions-in-european-union 2025-03-04T19:55:29+00:00 hourly 0.9 https://trial.medpath.com/news/478f78f219145a15/auxora-shows-63-mortality-reduction-in-covid-19-patients-with-acute-kidney-injury 2025-03-04T19:55:08+00:00 hourly 0.9 https://trial.medpath.com/news/9572de179f57b87c/major-pharma-companies-report-promising-phase-3-results-for-chronic-rhinosinusitis-treatment 2025-03-04T19:54:51+00:00 hourly 0.9 https://trial.medpath.com/news/4c23349170119235/masitinib-shows-promise-in-progressive-ms-treatment-leading-neurologist-highlights-novel-mechanism-of-action 2025-03-04T19:54:30+00:00 hourly 0.9 https://trial.medpath.com/news/ec0acf078ebeb01b/ga-depot-shows-promise-in-progressive-ms-with-3-year-stability-in-disability-scores 2025-03-04T19:54:09+00:00 hourly 0.9 https://trial.medpath.com/news/b1d442a96cca04dc/fda-fast-tracks-discure-s-novel-bioelectronic-treatment-for-degenerative-disc-disease 2025-03-04T19:53:50+00:00 hourly 0.9 https://trial.medpath.com/news/bab8e1ff0e391316/fda-approves-pivotal-trial-of-novel-device-for-post-prostatectomy-incontinence-treatment 2025-03-04T19:53:34+00:00 hourly 0.9 https://trial.medpath.com/news/7ce39b2c6dd97607/rsv-treatment-landscape-expands-with-new-vaccines-and-clinical-trials-in-2024-2025 2025-03-04T19:53:10+00:00 hourly 0.9 https://trial.medpath.com/news/a2139f6f39f815a5/cingulate-s-once-daily-adhd-drug-ctx-1301-shows-promising-safety-profile-in-phase-3-trials 2025-03-04T19:52:43+00:00 hourly 0.9 https://trial.medpath.com/news/be8347ed5dd0d149/biohaven-s-bhv-7000-fails-primary-endpoint-in-pivotal-bipolar-disorder-trial 2025-03-04T19:52:22+00:00 hourly 0.9 https://trial.medpath.com/news/bf41a68af4164924/novel-dual-drug-combination-shows-promise-in-treating-resistant-acute-myeloid-leukemia 2025-03-04T19:52:03+00:00 hourly 0.9 https://trial.medpath.com/news/d9e856cc797cd57c/simbec-orion-and-avance-clinical-form-strategic-global-cro-partnership-to-enhance-clinical-trial-capabilities 2025-03-04T19:51:43+00:00 hourly 0.9 https://trial.medpath.com/news/bf7edaa73d2556b6/lygenesis-s-phase-2a-liver-regeneration-trial-advances-to-higher-dosing-after-safety-milestone 2025-03-04T19:51:23+00:00 hourly 0.9 https://trial.medpath.com/news/e58ca122acf40954/verana-health-expands-site-explorer-tool-to-boost-diversity-in-clinical-trial-recruitment 2025-03-04T19:51:08+00:00 hourly 0.9 https://trial.medpath.com/news/aa1c5a501b172df4/cadrenal-therapeutics-partners-with-abbott-to-advance-novel-anticoagulant-trial-for-lvad-patients 2025-03-04T19:50:48+00:00 hourly 0.9 https://trial.medpath.com/news/d22dc1534bc95d6b/icon-and-mural-health-partner-to-streamline-clinical-trial-participant-experience-with-digital-payment-platform 2025-03-04T19:50:30+00:00 hourly 0.9 https://trial.medpath.com/news/ac5c64f836a2c627/allurion-technologies-secures-new-patents-for-next-generation-obesity-treatment-device 2025-03-04T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/8da20c84e59ad395/ku-leuven-and-uz-leuven-launch-eur14-million-advanced-therapy-production-facility 2025-03-04T15:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/a847d44a3a666cb2/pharmacists-critical-role-in-improving-access-and-affordability-of-breast-cancer-therapies 2025-03-04T14:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/88f2ce0a242ee340/fairjourney-biologics-expands-global-footprint-with-acquisition-of-charles-river-s-superhuman-antibody-platform 2025-03-04T13:38:56+00:00 hourly 0.9 https://trial.medpath.com/news/19de9c1387476f43/abbvie-terminates-rova-t-development-after-5-8b-stemcentrx-deal-becomes-major-r-d-setback 2025-03-04T13:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/e7dde1fa8f5394f2/enhertu-demonstrates-significant-overall-survival-benefit-in-her2-positive-breast-cancer-phase-iii-trial 2025-03-04T13:37:45+00:00 hourly 0.9 https://trial.medpath.com/news/bec319e1389c4af6/novel-autologous-cell-therapy-shows-92-success-rate-in-treating-limbal-stem-cell-deficiency 2025-03-04T13:37:24+00:00 hourly 0.9 https://trial.medpath.com/news/ec501ee5cff2a3c2/phenomix-sciences-revolutionizes-obesity-treatment-with-precision-medicine-approach 2025-03-04T13:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/22b89bac5c0ea64d/breakthrough-study-endometrial-immune-profiling-boosts-ivf-success-rates-by-40 2025-03-04T13:36:45+00:00 hourly 0.9 https://trial.medpath.com/news/327c97cf8cdb9570/verigraft-secures-eur1-2m-grant-to-develop-revolutionary-3d-printed-vascular-grafts 2025-03-04T13:36:30+00:00 hourly 0.9 https://trial.medpath.com/news/9ea6f3632f96fa57/eton-pharmaceuticals-launches-fda-approved-galzin-for-wilson-disease-maintenance-treatment 2025-03-04T13:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/3ca1b8cad7041ec7/sofinnova-partners-secures-eur1-2-billion-to-fuel-next-wave-of-biotech-innovation 2025-03-04T12:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/bd5cd04645a05c3e/dmc-approves-dose-escalation-in-spago-nanomedical-s-177lu-sn201-cancer-trial 2025-03-04T11:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/5c0459495f4fc00f/philips-initiates-class-i-recall-of-tack-endovascular-system-due-to-safety-concerns 2025-03-04T10:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/c744ca03d65a0031/milwaukee-va-emerges-as-top-center-for-veteran-cancer-clinical-trials-with-60-enrollment-rate 2025-03-04T07:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/0d90cfc109ee38a2/deepqure-s-novel-extravascular-rdn-device-shows-promise-in-global-hypertension-trials 2025-03-04T07:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/6da03215e36463c8/nih-funding-critical-for-addressing-gaps-in-pediatric-clinical-trials-study-reveals 2025-03-04T07:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/6bc1c41f187181d1/cybrexa-s-novel-peptide-drug-conjugates-show-promising-tumor-selective-activity-in-preclinical-studies 2025-03-04T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/0f39a49433930ddb/momentum-biotechnologies-acquires-omicscouts-to-expand-mass-spectrometry-based-drug-discovery-platform 2025-03-04T07:28:07+00:00 hourly 0.9 https://trial.medpath.com/news/728dabd69cc82670/bioxcel-therapeutics-secures-14m-through-direct-stock-offering-to-institutional-investors 2025-03-04T05:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/ad2b6e7cee1f236f/aura-biosciences-to-present-new-phase-1-data-for-bel-sar-in-bladder-cancer-at-eau-2025 2025-03-04T05:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/bf3e4fd9da44c190/boston-scientific-expands-hypertension-portfolio-with-540m-acquisition-of-israeli-tech-firm 2025-03-04T05:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/85381c7d72180ab1/boston-scientific-acquires-sonivie-for-540m-expanding-into-renal-denervation-market 2025-03-04T04:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/25507870af14de25/fda-approves-ind-for-laekna-s-novel-usp1-inhibitor-lae120-for-advanced-solid-tumors 2025-03-04T04:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/1ac452e452a2a4a8/ubrigene-biosciences-advances-cell-therapy-development-with-dmf-submission-for-ipsc-reprogramming-kit 2025-03-04T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e3a77e8587a5b8ab/adverum-launches-groundbreaking-phase-3-artemis-trial-for-one-time-gene-therapy-in-wet-amd 2025-03-04T01:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/2d0400784d944bbc/fda-budget-cuts-under-trump-administration-threaten-drug-development-pipeline 2025-03-04T01:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/520b8c92bcf7a44d/onward-medical-secures-2-5m-in-grants-to-explore-arc-im-system-for-parkinson-s-disease-symptoms 2025-03-04T01:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/7e03ea10652291ce/centauri-therapeutics-advances-novel-immunotherapy-against-gram-negative-bacterial-infections-to-clinical-stage 2025-03-04T01:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/b35b35776a88a1a6/novel-il-12-delivery-system-shows-promise-for-advanced-ovarian-cancer-treatment 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/b9eaea64ae779b8b/abbvie-diversifies-portfolio-with-fda-priority-review-for-upadacitinib-as-humira-faces-biosimilar-competition 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/7534c517d2d9b132/regeneron-leads-60-million-consortium-to-accelerate-uk-biobank-genome-sequencing-for-alzheimer-s-and-parkinson-s-drug-discovery 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/9bdc7384a911c3c8/novel-drug-combination-overcomes-resistance-in-braf-mutated-melanoma-prevents-brain-metastasis 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/e9aa50d6b1cf6410/acp-711-shows-promising-safety-profile-in-phase-1-multiple-ascending-dose-study-for-essential-tremor 2025-03-03T23:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/624010730378f335/vaxcyte-nears-critical-phase-ii-readout-for-24-valent-pneumococcal-vaccine 2025-03-03T22:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/058f4fb49c67343f/malaria-drug-pyronaridine-shows-promise-as-novel-cancer-treatment 2025-03-03T22:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/4a752f73edffeb15/ema-s-chmp-recommends-four-new-medicines-for-approval-reaffirms-leqembi-decision 2025-03-03T22:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/72ce2c7d6a486d1c/fda-approves-ani-pharmaceuticals-cortrophin-gel-prefilled-syringe-for-multiple-autoimmune-conditions 2025-03-03T22:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/eb5e1940f7835876/jak-inhibitors-pipeline-expands-with-55-drug-candidates-as-major-pharma-companies-drive-innovation 2025-03-03T22:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/a7ac8f1ba83d63b9/tenaya-therapeutics-launches-public-offering-to-advance-cardiac-gene-therapy-pipeline 2025-03-03T21:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/6d807c5c89237fc3/praxis-precision-s-essential-tremor-trial-halted-after-disappointing-interim-analysis 2025-03-03T21:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/3f4b867b4aef6a7e/deucrictibant-shows-promising-long-term-safety-and-efficacy-in-hereditary-angioedema-treatment 2025-03-03T19:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/0431d37a50ec5911/berberine-based-drug-htd1801-shows-promising-results-in-type-2-diabetes-phase-2-trial 2025-03-03T19:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/0fb6b220d5a17fcb/selpercatinib-shows-sustained-long-term-efficacy-in-ret-fusion-positive-nsclc-patients 2025-03-03T19:35:24+00:00 hourly 0.9 https://trial.medpath.com/news/83496e7f1bb439f0/protagonist-and-takeda-s-rusfertide-shows-positive-phase-3-results-in-polycythemia-vera 2025-03-03T19:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/6b3b9365c5b1facf/praxis-precision-faces-setback-as-essential-tremor-drug-trial-falls-short-of-expectations 2025-03-03T19:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/624e01d5c420d91d/uc-santa-cruz-clinical-lab-receives-clia-certification-for-revolutionary-pediatric-cancer-rna-testing 2025-03-03T19:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/0d6a9613b0469baa/eco-animal-health-submits-first-eu-vaccine-application-for-poultry-mycoplasma-treatment 2025-03-03T19:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/32b3aebd8b32a480/robust-pipeline-of-220-drugs-advancing-for-gastric-cancer-treatment-led-by-major-pharmaceutical-companies 2025-03-03T19:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/df104be766aaa018/robust-pipeline-for-ewing-sarcoma-treatment-25-companies-advancing-novel-therapies 2025-03-03T19:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/dc6be97a1c1a1af4/aion-healthspan-launches-first-human-trial-of-rejuvxl-cell-therapy-for-chronic-kidney-disease 2025-03-03T19:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/15685394c4bd6e71/fresenius-launches-otulfi-new-stelara-biosimilar-in-us-and-european-markets 2025-03-03T19:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/9249ae33baf347f1/fda-approves-genentech-s-tnkase-for-acute-ischemic-stroke-with-simplified-administration 2025-03-03T19:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/0d0b279d2bc4c3b9/myosin-therapeutics-secures-3m-in-second-seed-funding-to-advance-brain-cancer-and-addiction-therapies 2025-03-03T19:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/eb6e610dc18904ee/fda-grants-orphan-drug-designation-to-diagnamed-s-molecular-hydrogen-therapy-for-als 2025-03-03T18:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/e73e8198186032b7/fda-breakthrough-therapy-status-emerges-as-game-changer-for-oncology-drug-development 2025-03-03T17:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/da4ca0c5c9edfc37/arrivent-biopharma-secures-strong-financial-position-with-266-5m-cash-reserve-following-successful-ipo 2025-03-03T17:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/bab5a766ee8d2463/essential-tremor-drug-development-faces-setbacks-as-multiple-clinical-trials-report-disappointing-results 2025-03-03T17:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/143e250adce857c3/california-s-state-branded-insulin-program-faces-significant-delays-no-clear-launch-timeline 2025-03-03T17:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/be352b0323c8c34b/genevant-and-arbutus-launch-global-patent-battle-against-moderna-over-lnp-technology-in-covid-19-vaccine 2025-03-03T17:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/a7ae058189a50060/gensaic-and-novo-nordisk-partner-to-develop-novel-precision-therapeutics-platform 2025-03-03T17:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/3990f13acdb8be4c/elucid-strengthens-leadership-team-to-launch-ai-powered-atherosclerosis-analysis-software-plaqueiq 2025-03-03T17:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/c58827b16990a438/inka-health-pioneers-ai-driven-synthetic-patient-models-for-advancing-oncology-research 2025-03-03T16:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/6f64494376074a22/batteryless-neurostimulator-shows-promising-6-month-results-for-overactive-bladder-treatment 2025-03-03T16:39:51+00:00 hourly 0.9 https://trial.medpath.com/news/64c4fd97f7b08f3c/trilaciclib-shows-strong-myeloprotection-but-mixed-efficacy-results-in-metastatic-colorectal-cancer-trial 2025-03-03T16:39:30+00:00 hourly 0.9 https://trial.medpath.com/news/62e94ecbff99507e/fda-concludes-inspection-of-bioxcel-s-tranquility-ii-phase-3-trial-site-with-vai-status 2025-03-03T16:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/0b75a6df699e3242/oh2-oncolytic-virus-plus-hx008-shows-promise-in-advanced-sarcoma-treatment 2025-03-03T16:38:52+00:00 hourly 0.9 https://trial.medpath.com/news/8f1607fe622c6b61/first-patient-dosed-in-phase-1-trial-of-abs-0871-for-charcot-marie-tooth-disease-2c-treatment 2025-03-03T16:38:28+00:00 hourly 0.9 https://trial.medpath.com/news/5aa709f126f1ab84/wren-laboratories-launches-advanced-netest-2-0-for-enhanced-neuroendocrine-tumor-diagnostics 2025-03-03T16:38:11+00:00 hourly 0.9 https://trial.medpath.com/news/1f120e7098ffb4c2/ensysce-biosciences-pioneers-novel-opioids-with-built-in-overdose-prevention-technology 2025-03-03T16:37:52+00:00 hourly 0.9 https://trial.medpath.com/news/ea02284603ae3aa2/rome-therapeutics-landmark-study-reveals-novel-line-1-activity-patterns-across-cancer-types 2025-03-03T16:37:35+00:00 hourly 0.9 https://trial.medpath.com/news/5eba235001519981/fda-grants-fast-track-status-to-latigo-s-novel-non-opioid-pain-treatment-ltg-001 2025-03-03T16:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/7d7869eb88a6a7e1/mental-health-concerns-rise-as-weight-loss-drug-users-report-increased-anxiety-and-panic-attacks 2025-03-03T16:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/f4437574975d3764/revive-therapeutics-to-acquire-diagnamed-s-molecular-hydrogen-program-for-als-and-brain-disorders 2025-03-03T16:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/5334311b84d4f9b2/gilead-sciences-prepares-for-major-launch-of-long-acting-hiv-prevention-drug 2025-03-03T16:36:15+00:00 hourly 0.9 https://trial.medpath.com/news/20101ee7a836ab0a/nuvation-bio-secures-250m-financing-package-to-launch-novel-lung-cancer-drug-taletrectinib 2025-03-03T16:35:53+00:00 hourly 0.9 https://trial.medpath.com/news/f66cbdcfaa2696d1/callio-therapeutics-secures-187m-series-a-to-develop-novel-multi-payload-cancer-adcs 2025-03-03T16:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/724c3a0a9c8a121a/lexicon-s-non-opioid-pain-drug-pilavapadin-misses-primary-endpoint-in-phase-iib-diabetic-neuropathy-trial 2025-03-03T16:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/c47d1ccc80c75fc1/rusfertide-shows-promising-results-in-phase-3-trial-for-polycythemia-vera-treatment 2025-03-03T16:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/53d986acccac1434/european-commission-approves-first-chikungunya-vaccine-from-bavarian-nordic 2025-03-03T16:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/af2c67ff89bca6de/biond-biologics-reclaims-bnd-22-rights-from-sanofi-following-promising-phase-1-results-in-cancer-treatment 2025-03-03T16:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/3eeb765bb0480e2f/marengo-and-ipsen-advance-second-novel-t-cell-activator-drug-candidate-for-cancer-immunotherapy 2025-03-03T16:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/fcd4db94c409be07/global-clinical-trials-for-myelodysplastic-syndrome-show-significant-industry-investment-in-2025 2025-03-03T16:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/bcbc33fb5bedcf30/ema-launches-interactive-clinical-trials-map-to-boost-patient-engagement-in-eu-studies 2025-03-03T16:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/ac1cd0f56e45bf91/nexalin-secures-uspto-patent-allowance-for-novel-non-invasive-addiction-treatment-technology 2025-03-03T16:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/68a77cc312e085a1/akari-therapeutics-secures-7-6-million-private-placement-to-advance-novel-adc-platform 2025-03-03T14:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/0159d6d9cea0ee3b/naxitamab-shows-promising-results-in-phase-2-trial-for-high-risk-neuroblastoma 2025-03-03T14:01:55+00:00 hourly 0.9 https://trial.medpath.com/news/be6ec530c2be12db/mbx-biosciences-completes-enrollment-in-phase-2-trial-of-canvuparatide-for-hypoparathyroidism 2025-03-03T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/392b075e38988695/esperion-expands-global-reach-new-partnerships-with-csl-seqirus-and-hls-therapeutics-for-nexletol-and-nexlizet 2025-03-03T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/760e5e2ebe4d542a/immunitybio-achieves-multiple-milestones-in-q1-2024-advances-anktiva-development-with-rmat-designation 2025-03-03T13:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/233622bdc5aa5b2f/metis-pharmaceuticals-strengthens-leadership-team-with-appointment-of-mark-herbert-as-chief-business-officer 2025-03-03T13:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/b90da187115fba34/vegen-labs-receives-3-765-crore-birac-grant-to-advance-novel-kras-inhibitor-for-lung-cancer-treatment 2025-03-03T13:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/987f030c8e7f6ad7/ideaya-and-attmos-partner-to-pioneer-ai-driven-drug-discovery-for-undruggable-cancer-targets 2025-03-03T13:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/3a50859cd8c5aa09/fda-grants-orphan-drug-designation-to-bexmarilimab-for-myelodysplastic-syndrome-treatment 2025-03-03T13:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/24d2a6599262551b/pulnovo-medical-raises-100m-to-advance-pulmonary-hypertension-treatment-development 2025-03-03T13:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/a4e63176fc69ecac/abbvie-enters-obesity-market-with-350m-gubra-deal-for-novel-amylin-analog 2025-03-03T13:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/ed123874d334ea76/gsk-s-novel-treatment-shows-promising-results-in-phase-iii-trials-for-chronic-rhinosinusitis-with-nasal-polyps 2025-03-03T13:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/3f6b987d73b4e944/breakthrough-gene-therapy-for-maple-syrup-urine-disease-shows-promise-in-animal-models 2025-03-03T10:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/35ae0e200a5d2153/roche-s-xolair-shows-promising-results-in-phase-iii-study-for-chronic-spontaneous-urticaria 2025-03-03T10:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/b0cc1a04391341c3/fda-declares-end-to-ozempic-shortage-while-australian-supply-remains-limited-until-2025 2025-03-03T10:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/b16868d6978a8bf4/eisai-launches-chocola-bb-nightwell-novel-sleep-time-fatigue-recovery-drink 2025-03-03T10:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/ac614c788710060f/shionogi-and-osaka-metropolitan-university-form-strategic-alliance-to-combat-infectious-diseases 2025-03-03T10:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/c6dca747049bded2/peptide-formulation-delivery-summit-to-address-key-challenges-in-therapeutic-development 2025-03-03T09:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/ea95ba0452b44e60/astrazeneca-s-durvalumab-tremelimumab-combination-approved-for-liver-cancer-treatment-in-india 2025-03-03T09:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/895d002924122d91/glenmark-expands-injectable-portfolio-with-acetylcysteine-acquisition-and-us-launch 2025-03-03T07:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/5ce0d1f100f9c7c7/ncx-470-shows-superior-iop-control-over-latanoprost-in-mont-blanc-trial-analysis 2025-03-03T07:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/b1f090dc9bb6d16e/blackstone-acquires-60-stake-in-cmic-to-accelerate-drug-development-in-japan 2025-03-03T07:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/b37b3018c83c59e1/compass-pathways-advances-revolutionary-psilocybin-treatment-comp360-into-phase-3-trials-for-treatment-resistant-depression 2025-03-03T04:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/6319f144c250ec33/novartis-partners-with-basgenbio-for-ai-powered-clinical-trial-simulation-in-breast-cancer-research 2025-03-03T04:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/e490de5221aa8e30/novel-fenugreek-based-nanoparticles-show-promise-in-enhancing-diabetes-drug-delivery 2025-03-03T04:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/2716c86e1a29fe22/pulnovo-medical-secures-100m-series-c-funding-to-advance-pulmonary-hypertension-treatment 2025-03-03T04:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/b87788cd1131a85e/clarity-pharmaceuticals-reports-widening-losses-amid-expanded-r-d-investment-in-radiopharmaceuticals 2025-03-03T04:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/7751cad5dcb30a6f/xolair-study-shows-promise-majority-of-children-successfully-consume-allergens-after-treatment-discontinuation 2025-03-03T02:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/d10223ca5c16e3c4/avecho-and-sandoz-partner-in-landmark-19m-deal-to-develop-otc-cbd-insomnia-treatment 2025-03-03T01:33:25+00:00 hourly 0.9 https://trial.medpath.com/news/1855f4169f424753/fda-greenlights-amplia-s-protocol-for-narmafotinib-folfirinox-combination-trial-in-advanced-pancreatic-cancer 2025-03-03T01:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/a8707e1ec69a21ff/xolair-shows-superior-efficacy-over-oral-immunotherapy-in-landmark-food-allergy-trial 2025-03-03T01:32:41+00:00 hourly 0.9 https://trial.medpath.com/news/d832662776be1c2a/early-leqembi-patient-s-journey-highlights-promise-and-limitations-of-new-alzheimer-s-treatment 2025-03-03T01:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/b2cc8d3de8ccea8d/hong-kong-s-car-t-cell-therapy-shows-promise-in-early-patient-testing 2025-03-03T01:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/9510d48108572599/tezepelumab-shows-79-reduction-in-severe-asthma-exacerbations-in-real-world-study 2025-03-03T01:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/1f2794c3d2723217/anaphylm-shows-consistent-efficacy-despite-oral-allergy-syndrome-complications 2025-03-03T01:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/55b5e9273befc358/fda-approves-first-generic-version-of-astrazeneca-s-symbicort-for-asthma-and-copd 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9fc8572880546d01/rising-sirturo-resistance-threatens-tb-treatment-progress-experts-call-for-new-therapies 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7f44d1997b005da9/biopharma-m-a-activity-reaches-79-4-billion-in-2024-despite-50-drop-from-previous-year 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/94be3364cac069ca/evolving-market-access-challenges-reshape-pharmaceutical-industry-strategy 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8008f84beab1c3fd/new-study-highlights-benefits-of-maintaining-high-factor-viii-levels-in-hemophilia-a-patients 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abec3c7b0d6ad8a3/pharma-field-forces-embrace-customer-centric-approach-in-digital-transformation-era 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8cadc56666e765ad/long-term-data-shows-no-survival-advantage-for-salvage-transplant-vs-lenalidomide-in-relapsed-multiple-myeloma 2025-03-02T22:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/0448c57955c32536/onco-innovations-advances-ai-driven-cancer-treatment-through-strategic-partnerships 2025-03-02T22:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/1e39ce03aa230b18/glenmark-pharmaceuticals-initiates-major-recall-of-adhd-medication-in-us-market 2025-03-02T19:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/7e27dc7a317a5566/novel-anti-ige-antibody-lp-003-shows-superior-efficacy-over-omalizumab-in-chronic-spontaneous-urticaria-trial 2025-03-02T19:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/955ebef429416088/herpes-zoster-vaccine-shows-strong-protection-for-stem-cell-transplant-recipients-meta-analysis-reveals 2025-03-02T19:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/d39c2a9950ce115b/dupilumab-shows-consistent-efficacy-in-eoe-treatment-independent-of-food-elimination-diets 2025-03-02T16:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/ed73bdc2470e3299/high-blood-eosinophils-and-feno-levels-predict-better-dupilumab-response-in-moderate-to-severe-asthma 2025-03-02T16:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/c34a4796ddce0fc6/fda-accepts-nivolumab-ipilimumab-combination-for-first-line-treatment-of-dmmr-msi-h-colorectal-cancer 2025-03-02T14:01:47+00:00 hourly 0.9 https://trial.medpath.com/news/73e2a02b525b3643/alto-s-alto-300-shows-promise-in-phase-2b-trial-for-treatment-resistant-depression 2025-03-02T13:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/4ab47ccb64e89e65/fda-clears-novabay-s-novel-dual-action-eye-infection-treatment-nvc-422-for-clinical-trials 2025-03-02T07:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/cb482cad3d10f4bf/fda-delays-toripalimab-review-for-nasopharyngeal-carcinoma-due-to-pending-manufacturing-site-inspection 2025-03-02T07:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/c8e946b704542163/actigraph-and-biofourmis-partner-to-advance-digital-data-collection-in-clinical-trials 2025-03-02T07:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/7741dca839159754/clinical-trial-diversity-crisis-dr-karen-winkfield-outlines-solutions-for-inclusive-patient-participation 2025-03-02T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/d558e031582d7a5f/qiagen-expands-molecular-biology-portfolio-with-sabiosciences-acquisition 2025-03-02T01:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/d634c34733591a41/zervimesine-shows-promise-in-dry-amd-treatment-with-positive-phase-2-data 2025-03-02T01:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/f053df71cde8b309/four-new-humira-biosimilars-launch-in-us-market-with-steep-discounts-up-to-85 2025-03-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9ed063970c3f3519/moderna-merck-s-personalized-cancer-vaccine-shows-strong-promise-in-advanced-melanoma-trial 2025-03-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/763cf758299140e6/nice-reverses-decision-approves-braftovi-erbitux-combination-for-braf-mutated-colorectal-cancer 2025-03-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d9f1ee8215fccd25/abbvie-and-galapagos-form-406-million-alliance-to-develop-novel-cystic-fibrosis-therapies 2025-03-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f50249d4bdd50d84/responsible-ai-integration-in-pharmaceutical-r-d-balancing-innovation-with-safety-and-ethics 2025-03-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/00b85a019c3ed320/sun-pharma-advances-novel-obesity-drug-development-with-global-launch-plans 2025-03-01T22:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/0a11859779fe6696/scientists-uncover-new-druggable-site-on-eif4e-protein-opening-path-for-novel-cancer-therapeutics 2025-03-01T22:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/35b0b747b361bd62/apogee-therapeutics-to-present-phase-1-apg990-trial-results-for-inflammatory-disease-treatment 2025-03-01T19:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/2b63262ff858d49d/pfizer-acquires-amplyx-pharmaceuticals-to-advance-novel-antifungal-development 2025-03-01T19:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/a231cf58c7c8c5f1/car-t-cell-therapy-auto4-shows-promise-in-treating-peripheral-t-cell-lymphoma 2025-03-01T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/a331ad722362e67a/caliway-biopharmaceuticals-secures-record-breaking-206m-ipo-advances-novel-fat-reduction-drug-development 2025-03-01T19:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/e81b41215d171072/battery-free-sacral-neuromodulation-device-shows-84-success-rate-in-treating-urinary-incontinence 2025-03-01T19:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/92bcb0bb3a0c814d/novel-light-therapy-trial-launches-to-combat-progressive-ms-related-fatigue 2025-03-01T19:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/470907b26afdc4ad/novel-radiotherapy-approach-helps-rectal-cancer-patients-avoid-permanent-stoma-surgery 2025-03-01T19:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/a7af0e266263206d/smithrx-expands-autoimmune-program-with-stelara-biosimilars-projects-14-5m-annual-savings 2025-03-01T17:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/12a5fd9897459230/biotech-giants-invest-34-billion-in-manufacturing-scale-up-for-weight-loss-drugs 2025-03-01T16:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/8d2be61b5741c088/diagnos-inc-pursues-fda-authorization-for-ai-powered-retinal-disease-detection-system 2025-03-01T16:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/6bde25eb7bbfbb2c/fda-issues-new-guidance-on-electronic-systems-in-clinical-trials-enhanced-data-integrity-and-digital-health-integration 2025-03-01T16:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/92d0a842e62ab9c5/candel-therapeutics-can-2409-shows-dramatic-survival-benefit-in-phase-2-pancreatic-cancer-trial 2025-03-01T10:32:17+00:00 hourly 0.9